var title_f30_50_31520="Patchy lesions Crohns Endosc";
var content_f30_50_31520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Asymmetric distribution of lesions in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 183px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Colonoscopy in Crohn's disease demonstrates the characteristic patchy erythema (left panel) and ulceration (right panel) that occur next to areas of normal mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31520=[""].join("\n");
var outline_f30_50_31520=null;
var title_f30_50_31521="Resisted peace sign for ulnar nerve motor function";
var content_f30_50_31521=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Resisted peace sign for ulnar nerve motor function",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulnar nerve function can be assessed by having the patient make a peace sign and then maintain it against resistance, as shown in the photograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31521=[""].join("\n");
var outline_f30_50_31521=null;
var title_f30_50_31522="Bilateral pectoralis flap";
var content_f30_50_31522=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Bilateral pectoralis flap to fill sternal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Bilateral pectoralis major flap dissection. The dashed vertical black line indicates the extent of undermining and dissection of the pectoralis major muscle needed to extend it over the sternum.",
"    <br>",
"     (B) Bilateral medial advancement and placement over mediastinal defect.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Orgill DP, Austen WG, Butler CE, et al. Guidelines for Treatment of Complex Chest Wounds with Negative Pressure Wound Therapy [review]. Wounds 2004; Suppl B: A compendium of clinical research and practice. Copyright &copy; 2004 HMP Communications, LLC.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31522=[""].join("\n");
var outline_f30_50_31522=null;
var title_f30_50_31523="Patient information: Hodgkin lymphoma in children (The Basics)";
var content_f30_50_31523=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83249\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/6/25702\">",
"         Lymphatic system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/27/17842\">",
"         Patient information: Hair loss from cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/10/23714\">",
"         Patient information: Hodgkin lymphoma in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/28/40386\">",
"         Patient information: Lymphoma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/7/18546\">",
"         Patient information: Preserving fertility after cancer treatment in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/59/43955\">",
"         Patient information: Swollen neck nodes in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/4/29762\">",
"         Patient information: When your cancer treatment makes you tired (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/37/13908\">",
"         Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hodgkin lymphoma in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hodgkin-lymphoma-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H8970230\">",
"      <span class=\"h1\">",
"       What is Hodgkin lymphoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hodgkin lymphoma is a type of lymphoma. Lymphoma is a cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make and store cells that fight infection (",
"      <a class=\"graphic graphic_figure graphicRef63854 \" href=\"mobipreview.htm?25/6/25702\">",
"       figure 1",
"      </a>",
"      ). Infection-fighting cells are also called &ldquo;white blood cells.&rdquo;",
"     </p>",
"     <p>",
"      When children have lymphoma, their white blood cells become abnormal, grow out of control, and travel to different parts of the body. The abnormal cells often collect in bean-shaped organs called lymph nodes. This makes the lymph nodes swell.",
"     </p>",
"     <p>",
"      Hodgkin lymphoma happens more often in teens than in younger children.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8970245\">",
"      <span class=\"h1\">",
"       What are the symptoms of Hodgkin lymphoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might see or feel a swollen, painless lymph node under your child&rsquo;s skin. Swollen lymph nodes are usually in the neck, above the collar bone, or in the armpit or groin.",
"     </p>",
"     <p>",
"      Lymph nodes deeper in the body can also become swollen and cause symptoms. For example, swollen lymph nodes in the chest can cause a cough, trouble swallowing, or trouble breathing.",
"     </p>",
"     <p>",
"      Other symptoms of Hodgkin lymphoma can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling very tired",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Weight loss or loss of appetite",
"       </li>",
"       <li>",
"        Night sweats that soak the clothes",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8970262\">",
"      <span class=\"h1\">",
"       Is there a test for Hodgkin lymphoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will ask about your child&rsquo;s symptoms and do an exam. He or she will also do:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A lymph node biopsy &ndash; A doctor will remove 1 of the swollen lymph nodes. Then another doctor will look at the cells under a microscope to see whether cancer cells are present.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8970277\">",
"      <span class=\"h1\">",
"       What is lymphoma staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lymphoma staging is a way in which doctors find out how far the lymphoma has spread in the lymphatic system or in the body.",
"     </p>",
"     <p>",
"      Hodgkin lymphoma usually starts in lymph nodes in the neck or chest. If the cancer spreads, it usually spreads to nearby lymph nodes, and then to organs such as the spleen or liver.",
"     </p>",
"     <p>",
"      To check how far your child&rsquo;s Hodgkin lymphoma has spread, the doctor will do an exam, blood tests, and imaging tests. Imaging tests, such as CT and PET scans, create pictures of the inside of the body.",
"     </p>",
"     <p>",
"      The doctor might also do a bone marrow biopsy. For this test, a doctor will take a small sample of bone marrow (the tissue in the middle of your child&rsquo;s bones). Then another doctor will look at the sample under a microscope to see whether it has cancer.",
"     </p>",
"     <p>",
"      The right treatment for your child will depend a lot on the stage of his or her Hodgkin lymphoma.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8970292\">",
"      <span class=\"h1\">",
"       How is Hodgkin lymphoma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. Doctors use different chemotherapy medicines to treat Hodgkin lymphoma. The doctor will work with you and your child to choose the ones that are right for your child.",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In most cases, Hodgkin lymphoma can be cured with treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8970307\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, the doctor will check your child every so often to see if the Hodgkin lymphoma comes back. Follow-ups can include talking with the doctor, exams, blood tests, and imaging tests.",
"     </p>",
"     <p>",
"      You should also watch your child for the symptoms listed above. Having those symptoms could mean the lymphoma has come back. Tell the doctor or nurse if your child has any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8970322\">",
"      <span class=\"h1\">",
"       What happens if the Hodgkin lymphoma comes back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the lymphoma comes back, your child might have more chemotherapy, radiation, or a bone marrow transplant. In a bone marrow transplant, the doctor replaces cells in the bone marrow that are killed by chemotherapy or radiation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8970337\">",
"      <span class=\"h1\">",
"       What else should my child and I know about treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some treatments for Hodgkin lymphoma can cause certain medical problems in the future.",
"     </p>",
"     <p>",
"      Talk with your child&rsquo;s doctor about these problems, so that you know what to watch for. You should also make sure that your child is followed long-term by a doctor who will check him or her for these problems later on.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8970352\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all of the doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to let the doctor know if your child has any side effects or problems during treatment.",
"     </p>",
"     <p>",
"      Hodgkin lymphoma treatment can involve making many choices, such as what treatment your child should have and when.",
"     </p>",
"     <p>",
"      Always let the doctors and nurses know how you feel about a treatment. Any time your child is offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help my child live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if my child does not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8970367\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/59/43955?source=see_link\">",
"       Patient information: Swollen neck nodes in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/28/40386?source=see_link\">",
"       Patient information: Lymphoma (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/10/23714?source=see_link\">",
"       Patient information: Hodgkin lymphoma in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/4/29762?source=see_link\">",
"       Patient information: When your cancer treatment makes you tired (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=see_link\">",
"       Patient information: Hair loss from cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18546?source=see_link\">",
"       Patient information: Preserving fertility after cancer treatment in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/37/13908?source=see_link\">",
"       Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/50/31523?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83249 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31523=[""].join("\n");
var outline_f30_50_31523=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8970230\">",
"      What is Hodgkin lymphoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8970245\">",
"      What are the symptoms of Hodgkin lymphoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8970262\">",
"      Is there a test for Hodgkin lymphoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8970277\">",
"      What is lymphoma staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8970292\">",
"      How is Hodgkin lymphoma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8970307\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8970322\">",
"      What happens if the Hodgkin lymphoma comes back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8970337\">",
"      What else should my child and I know about treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8970352\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8970367\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83249\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/6/25702\">",
"      Lymphatic system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/10/23714?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/28/40386?source=related_link\">",
"      Patient information: Lymphoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18546?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/59/43955?source=related_link\">",
"      Patient information: Swollen neck nodes in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_50_31524="Verrucous carcinoma Light";
var content_f30_50_31524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Verrucous carcinoma of the oral cavity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 275px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of verrucous carcinoma. The warty appearance is evident both grossly and microscopically, with a blunt pushing invasive border. A characteristic lymphocytic reaction is seen at the base of the lesion (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of G Kenneth Haines, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31524=[""].join("\n");
var outline_f30_50_31524=null;
var title_f30_50_31525="Location of spinal tumors";
var content_f30_50_31525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Location of spinal tumors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 495px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31525=[""].join("\n");
var outline_f30_50_31525=null;
var title_f30_50_31526="Evaluating response to treatment of multiple myeloma";
var content_f30_50_31526=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluating response to treatment of multiple myeloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/50/31526/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/50/31526/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/50/31526/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/50/31526/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/50/31526/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/50/31526/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/50/31526/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple myeloma is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. Potential complications include hypercalcemia, renal insufficiency, infection, and skeletal lesions. Once the diagnosis of multiple myeloma is made and it is determined that the patient requires therapy, treatment options include hematopoietic cell transplantation and chemotherapy.",
"   </p>",
"   <p>",
"    The International Myeloma Working Group has developed uniform response criteria, which are used to measure the effect of treatment. These criteria are described in detail here. This same group has proposed definitions of survival endpoints (ie, progression-free survival, time to progression, and duration of response) to be used in reporting clinical research. These are also defined here.",
"   </p>",
"   <p>",
"    Indications for the treatment of multiple myeloma, risk stratification, and the choice of initial therapy based on this risk stratification and patient characteristics are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28698?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of hematopoietic cell transplantation (HCT) in myeloma, chemotherapy in patients with relapsed or resistant myeloma, the treatment of complications of multiple myeloma (eg, hypercalcemia, renal insufficiency, skeletal lesions), and the use of bisphosphonates are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=see_link\">",
"     \"Treatment of relapsed or refractory multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/13/23769?source=see_link\">",
"     \"Treatment of the complications of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30137?source=see_link\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RESPONSE CRITERIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Myeloma Working Group (IMWG) uniform response criteria are the preferred criteria to determine the patient's best response to treatment and to define when a relapse has occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These criteria build upon the European Group for Blood and Marrow Transplant (EBMT) response criteria, which were widely used from 1998 until 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/3\">",
"     3",
"    </a>",
"    ]. In their revision of the EBMT criteria, the IMWG made some clarifications, added new categories of response, and incorporated the free light chain (FLC) assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=see_link&amp;anchor=H2212928#H2212928\">",
"     \"Recognition of monoclonal proteins\", section on 'Serum free light chains'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be evaluated before each treatment cycle to determine how their disease is responding to therapy. The preferred method is the measurement of monoclonal (M) protein in the serum and urine. Bone marrow evaluation is incorporated to identify complete response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/5\">",
"     5",
"    </a>",
"    ]. The free light chain (FLC) assay has allowed the determination of response in patients with unmeasurable disease by serum and urine protein electrophoresis and immunofixation electrophoresis. The use of FLC measurements in determining response to therapy is reserved for patients with unmeasurable protein in the serum and urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Definition of measurable disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Definition of measurable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the preferred method of following disease activity in patients with multiple myeloma is the serial measurement of monoclonal (M) protein in the serum or urine. Alternative methods include the evaluation of bone marrow plasma cell percentage and serum free light chain (FLC) measurements. FLC measurement is reserved for patients with unmeasurable M protein in the serum and urine (see definition of unmeasurable below). Bone marrow plasma cell assessment and imaging studies, such as",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI, are the only methods available for monitoring the small subset of myeloma patients that cannot be measured by M protein or FLC. The frequency of bone marrow assessment in these patients depends on other clinical parameters; patients who are felt to be responding well based on improvement in end-organ function will need bone marrow assessments less frequently compared with those in whom the response status is less clear. In addition to its role in response assessment for patients who lack measurable disease by M protein and FLC, a bone marrow assessment is also required for the determination of complete response.",
"   </p>",
"   <p>",
"    The following definitions of \"measurable\" disease apply when using the various assessment methods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monoclonal (M) protein &mdash; Serum M protein levels &ge;1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine M protein levels &ge;200",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      Serum FLC &mdash; An abnormal baseline serum FLC",
"      <span class=\"nowrap\">",
"       kappa/lambda",
"      </span>",
"      ratio (&lt;0.26 or &gt;1.65) most likely indicating clonality plus a baseline FLC level &ge;10",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      of the appropriate involved light chain isotype in the absence of severe renal failure. In patients with a FLC",
"      <span class=\"nowrap\">",
"       kappa/lambda",
"      </span>",
"      ratio &lt;0.26, lambda is the \"involved\" light chain and kappa is the \"uninvolved\" light chain. Conversely, in patients with an FLC ratio of &gt;1.65, kappa is the \"involved\" light chain and lambda is the \"uninvolved\" light chain.",
"     </li>",
"     <li>",
"      Bone marrow plasma cells &mdash; Baseline bone marrow plasma cell percentage of &ge;30 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Using M protein to assess response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of monoclonal (M) protein in the serum and urine is the preferred method to determine disease response and monitor for relapse if the patient has measurable M protein in the serum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urine.",
"   </p>",
"   <p>",
"    Serum M-protein is quantified using densitometry on serum protein electrophoresis (SPEP). If the spike is unmeasurable (eg, patients with small IgA M proteins located in the beta region), quantitative immunoglobulin levels (ie, IgA level measured by nephelometry) should be used instead. However, when comparing values, the method of protein measurement used for both values must be the same. Urine M-protein is quantified using densitometry on 24-hour urine protein electrophoresis (UPEP).",
"   </p>",
"   <p>",
"    Both serum and urine M-protein measurements are used to follow all patients because some patients who had positive serum studies on presentation will only show light chains on UPEP at the time of relapse. This is called \"light chain or Bence Jones escape\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These patients will typically also have an increased FLC level and an abnormal FLC ratio.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Using FLC levels to assess response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum free light chain (FLC) measurement is a useful method of monitoring patients without measurable M protein in the serum and urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/9\">",
"     9",
"    </a>",
"    ]. It also provides a more rapid way to evaluate response to treatment in patients with abnormal baseline FLC, because of its significantly shorter half-life than the monoclonal IgG or IgA. However, not all patients need FLC monitoring:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      FLC levels are most informative in patients who lack measurable M protein in the serum and urine (ie, serum M protein &lt;1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and urine M protein &lt;200",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"     </li>",
"     <li>",
"      FLC levels can be used only if the baseline FLC ratio is abnormal (&lt;0.26 or &gt;1.65) indicating clonality. In addition, the baseline FLC level must be &ge;10",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      of the appropriate involved light chain isotype.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A small subset of myeloma patients lack measurable M protein in the serum and urine, and also have either a normal FLC ratio or involved FLC level",
"    <span class=\"nowrap\">",
"     &lt;10mg/dL.",
"    </span>",
"    These patients can only be monitored by bone marrow plasma cell assessment and imaging studies as discussed above. Hemoglobin, calcium, creatinine measurements, and metastatic bone surveys are also useful in following these patients. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Using bone marrow plasma cells to assess response'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Further discussion on the use of FLC measurement in plasma cell disorders is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10618?source=see_link&amp;anchor=H13#H13\">",
"     \"Staging and prognostic studies in multiple myeloma\", section on 'Serum free light chain ratio'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/60/4041?source=see_link&amp;anchor=H22391048#H22391048\">",
"     \"Clinical course and management of monoclonal gammopathy of undetermined significance\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Using bone marrow plasma cells to assess response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow plasma cells can be used to assess response if the patient lacks measurable M protein levels in the serum and urine as defined earlier, as well as unmeasurable levels of FLC. In order to follow disease activity, the baseline bone marrow plasma cell percentage must be significant, typically &ge;30 percent. In addition, a bone marrow assessment is required for the determination of complete response.",
"   </p>",
"   <p>",
"    When using bone marrow to assess response, the percentage of plasma cells is usually determined by a morphologic evaluation and visual quantitation. While generally reserved for the research setting, quantitative assessment of residual disease in the bone marrow may also be performed using polymerase chain reaction or multiparametric flow cytometry. As described below, these studies are used to determine molecular complete response and immunophenotypic complete response, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/4\">",
"     4",
"    </a>",
"    ]. The clinical value of these more sensitive tests is yet to be determined, but is an area of active research. As an example, in a study of 241 patients with multiple myeloma who had attained a morphologic complete response following high dose chemotherapy followed by autologous hematopoietic cell transplantation, the presence of minimal residual disease detected by flow cytometry was associated with a greater chance of early relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Response categories'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24015559\">",
"    <span class=\"h3\">",
"     Imaging studies to measure response",
"    </span>",
"    &nbsp;&mdash;&nbsp;A metastatic bone survey with plain radiographs is a key component to the evaluation of a patient with multiple myeloma. While computerized tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) are more sensitive than plain radiographs at detecting bone involvement, the clinical importance of asymptomatic bone lesions is not well understood. As such they are not routinely incorporated into the response categories for myeloma. For the small subset of patients that have disease that cannot be measured by M protein or FLC measurements,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI offer a potential measure of residual disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Other imaging modalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial studies suggest that",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    can predict outcomes in patients with an initial response to therapy. As an example, the predictive value of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    was evaluated within the context of a prospective trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    followed by double autologous hematopoietic cell transplantation (HCT) in 192 patients with newly diagnosed multiple myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/11\">",
"     11",
"    </a>",
"    ]. When compared with those who had achieved PET negativity, patients with persistent FDG positive lesions three months after HCT had significantly inferior progression-free (hazard ratio [HR] 2.69; 95% CI 1.15-6.28) and overall (HR 3.93; 95% CI 1.15-13.42) survival.",
"   </p>",
"   <p>",
"    Further prospective studies comparing",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    with other measures of response (eg, flow cytometry, PCR) are necessary before",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    can be incorporated into standard practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Response categories",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response criteria are defined by the International Myeloma Working Group (IMWG) uniform response criteria as follows (",
"    <a class=\"graphic graphic_table graphicRef55362 \" href=\"mobipreview.htm?37/57/38813\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Molecular complete response &mdash; Achievement of a stringent complete response (defined below) plus no identifiable allele-specific oligonucleotides on polymerase chain reaction with a sensitivity of 10",
"      <sup>",
"       -5",
"      </sup>",
"      .",
"     </li>",
"     <li>",
"      Immunophenotypic complete response &mdash; Achievement of a stringent complete response plus no detectable phenotypically aberrant clonal plasma cells by &gt;4 color multiparametric flow cytometry on an analysis of bone marrow with a minimum of one million total bone marrow cells analyzed.",
"     </li>",
"     <li>",
"      Stringent complete response (sCR) &mdash; In addition to CR criteria (defined below), these patients have a normal free light chain ratio and have no clonal cells by bone marrow immunohistochemistry or immunofluorescence. Clonal cells detected in the bone marrow by immunohistochemistry or immunofluorescence are considered to be present if there is a",
"      <span class=\"nowrap\">",
"       kappa/lambda",
"      </span>",
"      ratio of &gt;4:1 or &lt;1:2 after examination of a minimum of 100 plasma cells.",
"     </li>",
"     <li>",
"      Complete response (CR) &mdash; Absence of monoclonal protein in serum and urine by immunofixation with no current evidence of soft tissue plasmacytoma. In addition, bone marrow aspirate and biopsy must demonstrate less than 5 percent clonal plasma cells. In patients who lack measurable M proteins in the serum and urine being monitored using the FLC levels, the definition of CR requires a normalization of the FLC ratio in addition to the above criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Very good partial response (VGPR) &mdash; Serum and urine M-protein detectable by immunofixation but not on electrophoresis or at least a 90 percent reduction in serum M-protein with a urine M-protein &lt;100",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours. In patients who lack measurable M proteins in the serum and urine being monitored using the FLC levels, the definition of VGPR requires &gt;90 percent decrease in the difference between involved and uninvolved free light chain levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Partial response (PR) &mdash; &ge;50 percent reduction in serum M-protein and reduction of 24-hour urinary M-protein by 90 percent or to &lt;200",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hr. In patients who lack measurable M proteins in the serum and urine, the definition of PR requires &ge;50 percent decrease in the difference between involved and uninvolved free light chain (FLC) levels. If the FLC levels were also unmeasurable at baseline, a 50 percent reduction in bone marrow plasma cells is acceptable as long as the original bone marrow contained at least 30 percent plasma cells. PR also requires a 50 percent reduction in size of any soft tissue plasmacytomas if present at baseline.",
"     </li>",
"     <li>",
"      Stable disease (SD) &mdash; Does not meet criteria for CR, VGPR, PR, or PD.",
"     </li>",
"     <li>",
"      Progressive disease (PD) &mdash; 25 percent increase from lowest response value in any of the following: serum M-protein (absolute increase must be &ge;0.5",
"      <span class=\"nowrap\">",
"       g/dl),",
"      </span>",
"      urine M-protein (absolute increase must be &ge;200",
"      <span class=\"nowrap\">",
"       mg/24hr),",
"      </span>",
"      bone marrow plasma cell percentage (absolute increase must be &ge;10 percent), or difference in the kappa and lambda FLC (absolute increase must be &gt;10",
"      <span class=\"nowrap\">",
"       mg/dl).",
"      </span>",
"      As discussed earlier, the FLC criteria should only be used for patients with unmeasurable M protein in the serum and urine. PD is also diagnosed when there is an increase in the size or development of new bone lesions or soft tissue plasmacytomas or the development of a serum calcium &gt;11.5",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      without other cause.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of including a bone marrow examination in the accurate estimation of complete response rates was perhaps best demonstrated in a study of 92 patients with previously measurable disease who had achieved negative serum and urine immunofixation following treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/5\">",
"     5",
"    </a>",
"    ]. After evaluation of a bone marrow biopsy, 79 patients (86 percent) demonstrated less than 5 percent plasma cells, while 13 patients (14 percent) had 5 percent or greater plasma cells, 11 of whom demonstrated monoclonality. When only patients with a normal serum FLC ratio and negative immunofixation of the urine and serum were analyzed, 3 of 26 patients (10 percent) demonstrated 5 percent or greater plasma cells in the bone marrow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SURVIVAL END POINTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective reviews have found that the amount of time that lapses before progression of myeloma may be a stronger predictor of a patient's survival when compared with the depth of their initial response to chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/12\">",
"     12",
"    </a>",
"    ]. Overall survival is markedly shortened for patients who experienced disease progression at 6 or 12 months. The rapidity with which the best response is obtained is also not necessarily a predictor for the duration of the subsequent response.",
"   </p>",
"   <p>",
"    As the importance of this response time is better understood, the International Myeloma Working Group (IMWG) has proposed uniform definitions of survival end points. Recommended end points are defined as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31526/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression-free survival: Time from start of treatment to disease progression or death from any cause.",
"     </li>",
"     <li>",
"      Time to progression: Time from start of treatment to disease progression. Deaths due to causes other than progression are censored, but not included in this calculation.",
"     </li>",
"     <li>",
"      Duration of response: For patients who have achieved a PR or greater response, this is the time from when the response was first noted until the time of disease progression. Deaths due to causes other than progression are censored, but not included in this calculation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of multiple myeloma is made and it is determined that the patient requires therapy, patients are followed at regular intervals to evaluate response to treatment. The standard criteria used to determine response were developed by the International Myeloma Working Group (IMWG) and have been in general use since 2006. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease response should be evaluated before each treatment cycle. The preferred method is the measurement of monoclonal (M) protein in the serum and urine. Bone marrow evaluation is incorporated to identify complete response. The free light chain (FLC) assay is most informative in patients with unmeasurable M protein in serum and urine. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Definition of measurable disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The IMWG response criteria are used to define response to therapy as stringent complete, complete, very good partial, and partial (",
"      <a class=\"graphic graphic_table graphicRef55362 \" href=\"mobipreview.htm?37/57/38813\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Response categories'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common definitions of survival endpoints (ie, progression-free survival, time to progression, and duration of response) should be used in reporting clinical research. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Survival end points'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31526/abstract/1\">",
"      Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31526/abstract/2\">",
"      Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31526/abstract/3\">",
"      Blad&eacute; J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31526/abstract/4\">",
"      Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117:4691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31526/abstract/5\">",
"      Chee CE, Kumar S, Larson DR, et al. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood 2009; 114:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31526/abstract/6\">",
"      Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008; 111:4908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31526/abstract/7\">",
"      Sawamura M, Murayama K, Tokizawa S, et al. Change of paraprotein from IgG lambda to lambda chain in myeloma. Ann Hematol 1993; 66:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31526/abstract/8\">",
"      Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007; 92:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31526/abstract/9\">",
"      Larson D, Kyle RA, Rajkumar SV. Prevalence and monitoring of oligosecretory myeloma. N Engl J Med 2012; 367:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31526/abstract/10\">",
"      Paiva B, Guti&eacute;rrez NC, Rosi&ntilde;ol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012; 119:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31526/abstract/11\">",
"      Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011; 118:5989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31526/abstract/12\">",
"      Durie BG, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 2004; 22:1857.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6648 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31526=[""].join("\n");
var outline_f30_50_31526=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RESPONSE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Definition of measurable disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Using M protein to assess response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Using FLC levels to assess response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Using bone marrow plasma cells to assess response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24015559\">",
"      - Imaging studies to measure response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Response categories",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SURVIVAL END POINTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6648\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6648|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/57/38813\" title=\"table 1\">",
"      IMWG response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/60/4041?source=related_link\">",
"      Clinical course and management of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28698?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10618?source=related_link\">",
"      Staging and prognostic studies in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30137?source=related_link\">",
"      The use of bisphosphonates in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_50_31527="Fiberoptic endotracheal intubation";
var content_f30_50_31527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Fiberoptic endotracheal intubation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 627px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Once the glottis is identified, the fiberoptic bronchoscope is advanced into the trachea to the level of the carina with the assistance of a standard laryngoscope.",
"    <br>",
"     (B) Using the fiberoptic bronchoscope as a guide, the endotracheal tube is inserted into the trachea.",
"     <br>",
"      (C) The bronchoscope is carefully removed while the endotracheal tube is held securely in place.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: King BR, Hagberg CA. Management of the difficult airway. In: Textbook of Pediatric Emergency Medicine Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"      </div>",
"      <div class=\"contractual\">",
"       <br/>",
"       <a href=\"file://www.lww.com\">",
"        file://www.lww.com",
"       </a>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31527=[""].join("\n");
var outline_f30_50_31527=null;
var title_f30_50_31528="Echocardiographic evaluation of the atria and appendages";
var content_f30_50_31528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Echocardiographic evaluation of the atria and appendages",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/50/31528/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/50/31528/contributors\">",
"     Elyse Foster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/50/31528/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/50/31528/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/50/31528/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/50/31528/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/50/31528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging of the right and left atria and their appendages can provide important diagnostic and prognostic information. Left atrial imaging is especially important in patients with atrial fibrillation who are at increased risk for thromboembolic events resulting from left atrial or atrial appendage thrombus. Imaging of the left atrium has gained increased importance in association with new investigational procedures for atrial appendage occlusion in patients with atrial fibrillation used for stroke prophylaxis.",
"   </p>",
"   <p>",
"    This topic will review the echocardiographic evaluation of the right and left atria and their appendages. The role of echocardiography in atrial fibrillation is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=see_link\">",
"     \"Role of echocardiography in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LEFT ATRIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left atrium can be easily imaged in a number of views by transthoracic (surface) or transesophageal echocardiography. In addition to being a site of thrombosis in atrial fibrillation, the left atrium can be involved in a number of disease processes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It commonly dilates with age through a process that seems to be linked to \"senile\" left ventricular diastolic dysfunction and other diseases affecting the left ventricle such as hypertrophic, dilated, or restrictive cardiomyopathy.",
"     </li>",
"     <li>",
"      Left atrial dilation occurs in association with chronic atrial fibrillation, Dilation can promote atrial fibrillation by perturbing propagation of orderly depolarization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/1\">",
"       1",
"      </a>",
"      ]. Conversely, permanent atrial fibrillation can promote LA dilation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12266?source=see_link\">",
"       \"Mechanisms of atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It dilates with mitral valve disease, including both mitral stenosis and mitral regurgitation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13610?source=see_link&amp;anchor=H11786166#H11786166\">",
"       \"Pathophysiology, clinical features, and evaluation of mitral stenosis\", section on 'Atrial fibrillation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It can be a site of infiltrative diseases such as amyloid cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It occasionally becomes compressed by intrathoracic neoplasms, descending aortic aneurysms, hiatal hernias, spinal deformity, or fluid.",
"     </li>",
"     <li>",
"      It is rarely involved in myocardial infarction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16615?source=see_link\">",
"       \"Supraventricular arrhythmias after myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is the most common site of origin of myxoma, the most common primary cardiac neoplasm. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=see_link\">",
"       \"Cardiac tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Left atrial size and function can be estimated from the M-mode echocardiogram although two-dimensional biplane or three-dimensional quantitation is preferred. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23146?source=see_link&amp;anchor=H5#H5\">",
"     \"Three-dimensional echocardiography\", section on 'Assessment of atrial volumes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     M-mode echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard M-mode image of the left atrium is taken from the long axis parasternal view and represents the anterior to posterior dimension of that structure (",
"    <a class=\"graphic graphic_figure graphicRef61898 \" href=\"mobipreview.htm?30/0/30725\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56155 \" href=\"mobipreview.htm?40/12/41152\">",
"     image 1",
"    </a>",
"    ). When using this methodology, it is critical to ensure that beam alignment is perpendicular to the long axis of the left atrium. This left atrial dimension is usually the smallest because of its shape and possibly its confinement between sternum and spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, this dimension is the least sensitive to left atrial enlargement but, when increased, is a highly specific indicator of dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11277739\">",
"    <span class=\"h3\">",
"     LA dimension",
"    </span>",
"    &nbsp;&mdash;&nbsp;One method for assessing left atrial size is to compare the left atrial dimension with the diameter of the aorta (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58902 \" href=\"mobipreview.htm?43/4/44096\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79751 \" href=\"mobipreview.htm?15/54/16228\">",
"     image 3",
"    </a>",
"    ). In normal subjects, these two measurements are about equal. As the left atrium enlarges, and in the absence of aortic dilatation, the left atrial diameter becomes significantly greater than that of the aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Two-dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left atrium can be visualized on two-dimensional transthoracic echocardiography from all of the standard imaging windows (parasternal, apical, subcostal). The left atrial size and volume, along with any other pathology, should be assessed. Transesophageal echocardiography can provide supplemental information about left atrial size and function and is of particular importance in the evaluation of left atrial thrombi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Transesophageal echocardiography'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11277746\">",
"    <span class=\"h3\">",
"     LA volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the irregular shape of the left atrium and the single and largely unrepresentative dimension represented by the M-mode image, volume estimates are preferred for evaluating the left atrium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/3\">",
"     3",
"    </a>",
"    ]. These measurements require two-dimensional images, preferably two orthogonal apical planes (apical four and two chamber view) (",
"    <a class=\"graphic graphic_figure graphicRef75128 \" href=\"mobipreview.htm?9/35/9778\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62320 \" href=\"mobipreview.htm?3/4/3138\">",
"     image 4",
"    </a>",
"    ). The volume estimations using an area-length algorithm as well as the biplane method of disks have been validated using angiography and contrast-enhanced cardiac CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the correlation between echocardiographic-derived left atrial volumes from the apical long axis and four chamber view with those obtained from contrast CT was very high if patients with very large atria (&gt;300 mL) were included (r = 0.98) and was still quite good if these patients were excluded (r = 0.82) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/6\">",
"       6",
"      </a>",
"      ]. The echocardiographic method underestimates atrial volume by approximately 23 percent and the reproducibility of the measurement has a two standard deviation value of 10 mL.",
"     </li>",
"     <li>",
"      In another study which used gated CT angiography with automated reconstruction, the two-dimensional echocardiographic technique underestimated LA volume by 38 mL, likely due a combination of poor endocardial definition of atrial borders and, to a lesser extent, by foreshortening of the atrium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The value of measuring left atrial volume to recognize pathology requires knowledge of normal population parameters. In males the volume is 18 to 58 mL, while in females it is 22 to 52 mL; the normal range for volume index is 21 to 28",
"    <span class=\"nowrap\">",
"     mL/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/8\">",
"     8",
"    </a>",
"    ]. By measuring the atrium during both systole and diastole, one can gain a concept of normal atrial function. Mean end-systolic left atrial volume in a group of normal males and females is 40 mL and its smallest volume at end-diastole (after emptying both passively and actively) is 25 mL. If the normal forward stroke volume of the left ventricle is 65 mL, 15 mL comes from emptying of the atrial reservoir and 50 mL flows directly from the pulmonary veins across the mitral valve, ie, conduit volume.",
"   </p>",
"   <p>",
"    Based upon mitral Doppler profiles of flow, most of reservoir left ventricular inflow (as contrasted with conduit flow) in the healthy young heart at normal heart rates enters by active left ventricular relaxation with relaxation of the atrial elastic forces (",
"    <a class=\"graphic graphic_waveform graphicRef59321 \" href=\"mobipreview.htm?5/31/5618\">",
"     waveform 1",
"    </a>",
"    ). Atrial contraction accounts for only about 10 mL of atrial transport in the healthy young heart; this value more than doubles with aging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Progress in developing atrial functional indices has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reservoir function can be estimated according to the formula (100[LA volume",
"      <sub>",
"       max",
"      </sub>",
"      &ndash; LA",
"      <span class=\"nowrap\">",
"       volume",
"       <sub>",
"        min",
"       </sub>",
"       /",
"      </span>",
"      LA volume",
"      <sub>",
"       max",
"      </sub>",
"      ]).",
"     </li>",
"     <li>",
"      Conduit function can be estimated by the equation (100[LA volume",
"      <sub>",
"       max",
"      </sub>",
"      &ndash; LA",
"      <span class=\"nowrap\">",
"       volume",
"       <sub>",
"        preA",
"       </sub>",
"       /",
"      </span>",
"      LA volume",
"      <sub>",
"       max",
"      </sub>",
"      ]).",
"     </li>",
"     <li>",
"      Contractile function can be calculated using the equation (100[LA volume",
"      <sub>",
"       preA",
"      </sub>",
"      &ndash; LA",
"      <span class=\"nowrap\">",
"       volume",
"       <sub>",
"        min",
"       </sub>",
"       /",
"      </span>",
"      LA volume",
"      <sub>",
"       preA",
"      </sub>",
"      ]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical utility of measuring these variables on a routine basis has not been established. Measures of left atrial strain and strain rate have also been applied in research studies.",
"   </p>",
"   <p>",
"    Echocardiography has also been used to estimate the prevalence of left atrial enlargement in the general population. In a report from the Mayo Clinic, a random sample of over 2000 residents of Olmsted County (age &ge;45) underwent echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/13\">",
"     13",
"    </a>",
"    ]. The prevalence of left atrial enlargement was 18 percent in men and 12 percent in women using left atrial diameter and 16 percent in both sexes using left atrial volume, both corrected for body surface area. Left atrial enlargement was thought to reflect the burden of cardiovascular disease. Left atrial dilatation is a powerful predictor of heart failure, stroke, and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/14-18\">",
"     14-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Society of Echocardiography recommends a value of 28",
"    <span class=\"nowrap\">",
"     ml/m2",
"    </span>",
"    as the upper limit for normal left atrial volume index, and a value of &gt;40",
"    <span class=\"nowrap\">",
"     ml/m2",
"    </span>",
"    for severe dilatation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11277753\">",
"    <span class=\"h3\">",
"     LA thrombus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of transthoracic echocardiography to identify or exclude left atrial or atrial appendage thrombi is limited, with a reported sensitivity of 40 to 60 percent, due largely to poor visualization of the left atrial appendage, where most atrial thrombi reside [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In our clinical experience, few if any left atrial appendage thrombi can be detected in this manner. With this in mind, transesophageal echocardiography is the preferred technique for detection of left atrial thrombi. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Detection of thrombi'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transesophageal echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the left atrium and even the left atrial appendage can be imaged with transthoracic echocardiography (",
"    <a class=\"graphic graphic_movie graphicRef88545 \" href=\"mobipreview.htm?4/11/4273\">",
"     movie 1",
"    </a>",
"    ), transesophageal echocardiography (TEE) permits detailed examination of most of the left atrium, including excellent views of the left atrial appendage. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Left atrial appendage'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Detection of thrombi",
"    </span>",
"    &nbsp;&mdash;&nbsp;TEE is the preferred approach for the detection of thrombi in the left atrium and appendage, given it is far more sensitive than transthoracic echocardiography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64942 \" href=\"mobipreview.htm?25/28/26050\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66980 \" href=\"mobipreview.htm?17/50/18223\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef73470 \" href=\"mobipreview.htm?25/10/25775\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef51472 \" href=\"mobipreview.htm?10/61/11231\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef64234 \" href=\"mobipreview.htm?30/38/31343\">",
"     movie 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef56080 \" href=\"mobipreview.htm?23/51/24383\">",
"     movie 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef66795 \" href=\"mobipreview.htm?4/61/5072\">",
"     movie 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In one study of patients undergoing mitral valve surgery, for example, TEE was 93 percent sensitive and 100 percent specific for thrombus, whereas the sensitivity of transthoracic echocardiography was only 53 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unless thrombi are very large and extend into the body of the left atrium, they are rarely identified by transthoracic echocardiography because the atrium lies in the far field of the interrogating ultrasound beam [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/21\">",
"     21",
"    </a>",
"    ]. However, in one multicenter study, two atrial appendage thrombi were identified on TTE using harmonic imaging and left-sided echocardiographic contrast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/22\">",
"     22",
"    </a>",
"    ]. Although the left atrial appendage and its internal architecture (including thrombi) are readily imaged by transesophageal echocardiography, only its outline is apparent by transthoracic echocardiography.",
"   </p>",
"   <p>",
"    Left atrial thrombi are present on TEE in approximately 13 percent of nonanticoagulated patients with atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/23-25\">",
"     23-25",
"    </a>",
"    ] and more often (33 percent in one series) in patients with rheumatic mitral stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. Among patients with atrial fibrillation who have had an acute thromboembolic event, residual thrombus is rarely seen on transthoracic echocardiography but can be detected by TEE in approximately 45 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Left atrial thrombi are often multiple and vary in size and, although they attach to the atrial wall, they usually demonstrate some degree of independent motion. Small thrombi must be distinguished from the normal trabeculations (pectinate muscles) of the left atrial appendage, and larger thrombi may be difficult to distinguish from tumor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The finding of spontaneous echo contrast, indicative of predisposing stasis, almost always accompanies thrombus and may be helpful in differentiating thrombi from tumor or normal anatomy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64942 \" href=\"mobipreview.htm?25/28/26050\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66980 \" href=\"mobipreview.htm?17/50/18223\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef73470 \" href=\"mobipreview.htm?25/10/25775\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef51472 \" href=\"mobipreview.htm?10/61/11231\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef66795 \" href=\"mobipreview.htm?4/61/5072\">",
"     movie 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=see_link\">",
"     \"Role of echocardiography in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Thrombus in sinus rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial thrombi infrequently occur in the setting of sinus rhythm. In one series of over 20,600 TEE examinations, a left atrial thrombus during sinus rhythm was detected in 0.1 percent of all examinations, accounting for 6 percent of all TEE examinations showing left atrial thrombus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/29\">",
"     29",
"    </a>",
"    ]. Atrial thrombus during sinus rhythm was usually associated with specific structural cardiac abnormalities (left ventricular dysfunction or mitral valve disease)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a history of atrial fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11278595\">",
"    <span class=\"h3\">",
"     Left atrial masses and tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to thrombi, the left atrium may be the site of other masses and tumors. Myxoma is the most common tumor seen in the left atrium (",
"    <a class=\"graphic graphic_movie graphicRef53680 \" href=\"mobipreview.htm?2/22/2402\">",
"     movie 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef64739 \" href=\"mobipreview.htm?34/44/35522\">",
"     movie 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75740 \" href=\"mobipreview.htm?25/55/26481\">",
"     image 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60232 \" href=\"mobipreview.htm?37/28/38338\">",
"     image 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68725 \" href=\"mobipreview.htm?33/53/34641\">",
"     image 9",
"    </a>",
"    ). These benign tumors most commonly arise from the inferior limb of the fossa ovale. They become manifest when they either embolize or cause obstruction to mitral inflow. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=see_link\">",
"     \"Cardiac tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The echocardiographic appearance of left atrial tumors can yield clues to their identity as myxoma; in some cases, a TEE is of more use (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60232 \" href=\"mobipreview.htm?37/28/38338\">",
"     image 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68725 \" href=\"mobipreview.htm?33/53/34641\">",
"     image 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the tumor is encapsulated, clear spaces that represent cysts and highly reflective patches representing calcification can be appreciated.",
"     </li>",
"     <li>",
"      Careful inspection of an encapsulated tumor also demonstrates the stalk of attachment at its typical location along the interatrial septum.",
"     </li>",
"     <li>",
"      If the tumor is more amorphous, its attachment is usually broad based and may have a polypoid appearance. The reflectance or ultrasonic brightness of these masses is much less vivid.",
"     </li>",
"     <li>",
"      Since myxomas are occasionally biatrial, careful inspection of the right atrium is warranted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LEFT ATRIAL APPENDAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left atrial appendage lies within the confines of the pericardium in close relation to the free wall of the left ventricle. The left atrial appendage is sometimes seen in the parasternal short axis through the cardiac base and the apical two chamber view [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/30\">",
"     30",
"    </a>",
"    ]. The left atrial appendage is long and thin with a narrow point of origin from the body of the left atrium. Its narrow, sharply pointed shape allows positive identification.",
"   </p>",
"   <p>",
"    The left atrial appendage is best evaluated by TEE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/30\">",
"     30",
"    </a>",
"    ]. The widespread use of this high resolution technique has led to the realization that clinically significant thrombi are commonly sequestered in this structure; these thrombi are rarely seen with transthoracic imaging (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64942 \" href=\"mobipreview.htm?25/28/26050\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef56080 \" href=\"mobipreview.htm?23/51/24383\">",
"     movie 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef66795 \" href=\"mobipreview.htm?4/61/5072\">",
"     movie 6",
"    </a>",
"    ). Thrombus has a predilection to form in the dysfunctional left atrial appendage perhaps because of its shape and the presence of trabeculations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/31\">",
"     31",
"    </a>",
"    ]. Similarly, in patients with mitral stenosis being considered for balloon mitral valvuloplasty, TEE is routinely performed to exclude thrombi in the left atrium and appendage so that catheter dislodgement can be avoided. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Detection of thrombi'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Left atrial appendage function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left atrial appendage is believed to function as a decompression chamber during left ventricular systole and other periods when left atrial pressure is elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/31\">",
"     31",
"    </a>",
"    ]. The function of the left atrial appendage on TEE has been studied in patients at risk for the development of left atrial thrombi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/30,32,33\">",
"     30,32,33",
"    </a>",
"    ]. A pulsed wave Doppler sample, placed within the left atrial appendage, reveals a characteristic pattern that is dependent upon the patient's underlying rhythm and atrial function (",
"    <a class=\"graphic graphic_waveform graphicRef54600 graphicRef78275 \" href=\"mobipreview.htm?32/0/32778\">",
"     waveform 2A-B",
"    </a>",
"    ). In patients with sinus rhythm, there are well-defined filling and emptying waves (peak emptying velocity &gt;55",
"    <span class=\"nowrap\">",
"     cm/sec),",
"    </span>",
"    appropriately timed with atrial contraction; there is a decrease in filling and emptying velocity of 2 and 4",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    for each 10 year increase in age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/34\">",
"     34",
"    </a>",
"    ]. However, among patients with atrial fibrillation, some have well-defined wave forms while others have low velocity, poorly defined wave forms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/30,32,33\">",
"     30,32,33",
"    </a>",
"    ]. Thrombi and spontaneous echo contrast are significantly more likely to occur in the latter group with low velocity wave forms. Additionally, in one study, left atrial appendage flow velocity was related to the ability to revert AF; a flow velocity &gt;31",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    was a predictor of electrical or pharmacologic cardioversion success (odds ratio 2.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/35\">",
"     35",
"    </a>",
"    ]. In another study, a left atrial appendage emptying velocity &gt;40",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    measured precardioversion was predictive of one-year maintenance of sinus rhythm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11050?source=see_link\">",
"     \"Cardioversion for specific arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RIGHT ATRIUM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Size",
"    </span>",
"    &nbsp;&mdash;&nbsp;M-mode techniques for measuring the right atrium have not been developed. Two-dimensional imaging can be accomplished from the four chamber and subcostal views and volumes can be measured using an area length algorithm by a single plane tracing from the four chamber view (",
"    <a class=\"graphic graphic_figure graphicRef60736 \" href=\"mobipreview.htm?28/12/28867\">",
"     figure 3",
"    </a>",
"    ). Most often, the size of the right atrium is judged qualitatively by comparing it to the left atrium and the right ventricle. Normally, the atria appear to be similar in size and smaller than their respective ventricle. Limited data on normal values using single plane method of discs for right atrial volume suggested that it is similar in size to the left atrium in males but slightly smaller in females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/9\">",
"     9",
"    </a>",
"    ]. Data from a three-dimensional echocardiographic study showed that the mean right atrial volume among 35 normal subjects was 41 &plusmn; 13 mL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23146?source=see_link&amp;anchor=H5#H5\">",
"     \"Three-dimensional echocardiography\", section on 'Assessment of atrial volumes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal right atrial structures and their variants should be recognized to avoid confusion with pathologic lesions. The Eustachian valve is located at the junction of the inferior vena cava and the right atrium and it is prominent in some individuals. Rarely, it extends to insert on the interatrial septum and must be distinguished from cor triatriatum dexter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/38\">",
"     38",
"    </a>",
"    ]. The Chiari network is a more fenestrated mobile structure at the junction of the vena cavae and the right atrium. Although these structures generally lack clinical significance, Eustachian valve endocarditis has rarely been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, the presence of a large Eustachian valve or Chiari network in conjunction with a patent foramen ovale is associated with cryptogenic stroke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the left atrial appendage, the right atrial appendage is broad-based and less distinct in appearance. The trabeculations (pectinate muscles) extend toward the tricuspid valve and are not confined to the appendage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Right atrial thrombus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombus formation is less common in the right compared to the left atrium. It occurs in association with in-dwelling catheters, especially at the junction of the superior vena cava and right atrium.",
"   </p>",
"   <p>",
"    Thrombi also can form in the right atrial appendage in patients with atrial fibrillation or prothrombotic states. However, the shallow anatomy of the right atrial appendage makes it a less likely site for thrombus formation. Among patients with AF, right atrial appendage thrombi occur in 3 to 6 percent of cases compared to approximately 13 percent with left atrial thrombi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/23-25,40\">",
"     23-25,40",
"    </a>",
"    ]. The majority of patients with right atrial thrombi also have left atrial thrombi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/41\">",
"     41",
"    </a>",
"    ]. Cardioversion should be deferred even if patients have isolated right atrial thrombi.",
"   </p>",
"   <p>",
"    Pulmonary emboli can rarely be imaged in transit or entrapped within the right atrium. On occasion, an embolus will become enmeshed in the foramen ovale as it paradoxically passes from right atrium to left atrium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=see_link&amp;anchor=H8#H8\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\", section on 'Abnormalities of the interatrial septum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Right atrial tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors of the right atrium are unusual, and tend to become large before the onset of symptoms (",
"    <a class=\"graphic graphic_figure graphicRef81570 \" href=\"mobipreview.htm?31/15/31999\">",
"     figure 4",
"    </a>",
"    ). Because surface imaging is frequently difficult, TEE appears to have incremental value in the diagnosis and characterization of these lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. The most primary common benign cardiac neoplasm is myxoma, about 15 percent of which arise in the right atrium. Lipomas are also common primary right atrial tumors. As with the left atrium, angiosarcoma of the right atrium is the most common primary malignant cardiac tumor.",
"   </p>",
"   <p>",
"    A far more common cause of tumors within the right atrium are extensions of those that arise in the abdomen and pelvis, especially hepatoma and renal cell carcinoma, which directly invade the inferior vena cava and extend into the right heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Although subcostal surface imaging may define the tumor, TEE, especially the longitudinal bicaval view, can better elucidate the tumor arising from the inferior vena cava into the right atrium. Surgical excision may result in protracted palliation from symptoms of right-sided obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     VENA CAVA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inferior vena cava (IVC) and its junction with the right atrium can be visualized in the subcostal view by surface echocardiography, as well as in the bicaval TEE view. Inferior vena cava size and its respiratory variation can be used to estimate right atrial pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31528/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The superior vena cava (SVC) can also be visualized in the bicaval TEE view. This view permits visualization of the course of central lines in the SVC as well as transvenous pacemaker leads in the SVC extending into the right atrium and right ventricle. Catheter or lead associated vegetations or thrombus may be identified, although artifact and acoustic windows may limit visualization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11277353\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The left atrium can be easily imaged in a number of views by transthoracic echocardiography. Left atrial size and function can be estimated on transthoracic imaging using M-mode echocardiography, although two-dimensional biplane or three-dimensional quantitation is preferred. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Left atrium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the left atrium and even the left atrial appendage can be imaged with transthoracic echocardiography, transesophageal echocardiography (TEE) permits detailed examination of most of the left atrium, including excellent views of the left atrial appendage. TEE is the preferred approach for the detection of thrombi in the left atrium and appendage, given it is far more sensitive than transthoracic echocardiography. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Transesophageal echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transthoracic two-dimensional imaging of the right atrium can be accomplished from the four chamber and subcostal views, and volumes can be measured using an area length algorithm by a single plane tracing from the four chamber view. Normal right atrial structures and their variants (ie, Eustachian valve and Chiari network) should be recognized to avoid confusion with pathologic lesions. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Right atrium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The inferior vena cava (IVC) and its junction with the right atrium can be visualized in the subcostal view by transthoracic echocardiography, while the superior vena cava (SVC) is best visualized using TEE. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Vena cava'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/1\">",
"      Goldman JH, Ehlgen A, Ursell PC, Schiller NB. Left atrial size is a poor predictor of pathology in the older patient: preliminary observations. Echocardiography 2006; 23:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/2\">",
"      Schabelman S, Schiller NB, Silverman NH, Ports TA. Left atrial volume estimation by two-dimensional echocardiography. Cathet Cardiovasc Diagn 1981; 7:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/3\">",
"      Lester SJ, Ryan EW, Schiller NB, Foster E. Best method in clinical practice and in research studies to determine left atrial size. Am J Cardiol 1999; 84:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/4\">",
"      Nakai T, Lee RJ, Schiller NB, et al. The relative importance of left atrial function versus dimension in predicting atrial fibrillation after coronary artery bypass graft surgery. Am Heart J 2002; 143:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/5\">",
"      Block M, Hourigan L, Bellows WH, et al. Comparison of left atrial dimensions by transesophageal and transthoracic echocardiography. J Am Soc Echocardiogr 2002; 15:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/6\">",
"      Kircher B, Abbott JA, Pau S, et al. Left atrial volume determination by biplane two-dimensional echocardiography: validation by cine computed tomography. Am Heart J 1991; 121:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/7\">",
"      Koka AR, Gould SD, Owen AN, Halpern EJ. Left atrial volume: comparison of 2D and 3D transthoracic echocardiography with ECG-gated CT angiography. Acad Radiol 2012; 19:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/8\">",
"      Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/9\">",
"      Thomas L, Levett K, Boyd A, et al. Compensatory changes in atrial volumes with normal aging: is atrial enlargement inevitable? J Am Coll Cardiol 2002; 40:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/10\">",
"      Thomas L, Levett K, Boyd A, et al. Changes in regional left atrial function with aging: evaluation by Doppler tissue imaging. Eur J Echocardiogr 2003; 4:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/11\">",
"      Thomas L, Thomas SP, Hoy M, et al. Comparison of left atrial volume and function after linear ablation and after cardioversion for chronic atrial fibrillation. Am J Cardiol 2004; 93:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/12\">",
"      Thomas L, Boyd A, Thomas SP, et al. Atrial structural remodelling and restoration of atrial contraction after linear ablation for atrial fibrillation. Eur Heart J 2003; 24:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/13\">",
"      Pritchett AM, Jacobsen SJ, Mahoney DW, et al. Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol 2003; 41:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/14\">",
"      Ristow B, Ali S, Whooley MA, Schiller NB. Usefulness of left atrial volume index to predict heart failure hospitalization and mortality in ambulatory patients with coronary heart disease and comparison to left ventricular ejection fraction (from the Heart and Soul Study). Am J Cardiol 2008; 102:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/15\">",
"      Di Tullio MR, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of ischemic stroke in an ethnically mixed population. Stroke 1999; 30:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/16\">",
"      Moller JE, Hillis GS, Oh JK, et al. Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation 2003; 107:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/17\">",
"      Sakaguchi E, Yamada A, Sugimoto K, et al. Prognostic value of left atrial volume index in patents with first acute myocardial infarction. Eur J Echocardiogr 2011; 12:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/18\">",
"      Zile MR, Gottdiener JS, Hetzel SJ, et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011; 124:2491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/19\">",
"      Manning WJ, Weintraub RM, Waksmonski CA, et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann Intern Med 1995; 123:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/20\">",
"      Hwang JJ, Chen JJ, Lin SC, et al. Diagnostic accuracy of transesophageal echocardiography for detecting left atrial thrombi in patients with rheumatic heart disease having undergone mitral valve operations. Am J Cardiol 1993; 72:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/21\">",
"      Pearson AC, Labovitz AJ, Tatineni S, Gomez CR. Superiority of transesophageal echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology. J Am Coll Cardiol 1991; 17:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/22\">",
"      Sallach JA, Puwanant S, Drinko JK, et al. Comprehensive left atrial appendage optimization of thrombus using surface echocardiography: the CLOTS multicenter pilot trial. J Am Soc Echocardiogr 2009; 22:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/23\">",
"      Manning WJ, Silverman DI, Keighley CS, et al. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol 1995; 25:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/24\">",
"      Weigner MJ, Thomas LR, Patel U, et al. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med 2001; 110:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/25\">",
"      Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/26\">",
"      Srimannarayana J, Varma RS, Satheesh S, et al. Prevalence of left atrial thrombus in rheumatic mitral stenosis with atrial fibrillation and its response to anticoagulation: a transesophageal echocardiographic study. Indian Heart J 2003; 55:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/27\">",
"      Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med 1998; 128:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/28\">",
"      Manning WJ, Silverman DI, Waksmonski CA, et al. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch Intern Med 1995; 155:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/29\">",
"      Agmon Y, Khandheria BK, Gentile F, Seward JB. Clinical and echocardiographic characteristics of patients with left atrial thrombus and sinus rhythm: experience in 20 643 consecutive transesophageal echocardiographic examinations. Circulation 2002; 105:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/30\">",
"      Agmon Y, Khandheria BK, Gentile F, Seward JB. Echocardiographic assessment of the left atrial appendage. J Am Coll Cardiol 1999; 34:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/31\">",
"      Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart 1999; 82:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/32\">",
"      M&uuml;gge A, K&uuml;hn H, Nikutta P, et al. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol 1994; 23:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/33\">",
"      Jue J, Winslow T, Fazio G, et al. Pulsed Doppler characterization of left atrial appendage flow. J Am Soc Echocardiogr 1993; 6:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/34\">",
"      Agmon Y, Khandheria BK, Meissner I, et al. Left atrial appendage flow velocities in subjects with normal left ventricular function. Am J Cardiol 2000; 86:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/35\">",
"      P&aacute;link&aacute;s A, Antonielli E, Picano E, et al. Clinical value of left atrial appendage flow velocity for predicting of cardioversion success in patients with non-valvular atrial fibrillation. Eur Heart J 2001; 22:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/36\">",
"      Antonielli E, Pizzuti A, P&aacute;link&aacute;s A, et al. Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 2002; 39:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/37\">",
"      Quraini D, Pandian NG, Patel AR. Three-dimensional echocardiographic analysis of right atrial volume in normal and abnormal hearts: comparison of biplane and multiplane methods. Echocardiography 2012; 29:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/38\">",
"      Yavuz T, Nazli C, Kinay O, Kutsal A. Giant eustachian valve with echocardiographic appearance of divided right atrium. Tex Heart Inst J 2002; 29:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/39\">",
"      Sawhney N, Palakodeti V, Raisinghani A, et al. Eustachian valve endocarditis: a case series and analysis of the literature. J Am Soc Echocardiogr 2001; 14:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/40\">",
"      de Divitiis M, Omran H, Rabahieh R, et al. Right atrial appendage thrombosis in atrial fibrillation: its frequency and its clinical predictors. Am J Cardiol 1999; 84:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/41\">",
"      Rostagno C, Olivo G, Comeglio M, et al. Left atrial size changes in patients with paroxysmal lone atrial fibrillation. An echocardiographic follow-up. Angiology 1996; 47:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/42\">",
"      Reeder GS, Khandheria BK, Seward JB, Tajik AJ. Transesophageal echocardiography and cardiac masses. Mayo Clin Proc 1991; 66:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/43\">",
"      M&uuml;gge A, Daniel WG, Haverich A, Lichtlen PR. Diagnosis of noninfective cardiac mass lesions by two-dimensional echocardiography. Comparison of the transthoracic and transesophageal approaches. Circulation 1991; 83:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/44\">",
"      Alam M, Sun I, Smith S. Transesophageal echocardiographic evaluation of right atrial mass lesions. J Am Soc Echocardiogr 1991; 4:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/45\">",
"      Allen G, Klingman R, Ferraris VA, et al. Transesophageal echocardiography in the surgical management of renal cell carcinoma with intracardiac extension. J Cardiovasc Surg (Torino) 1991; 32:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/46\">",
"      Hasnain JU, Watson RJ. Transesophageal echocardiography during resection of renal cell carcinoma involving the inferior vena cava. South Med J 1994; 87:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/47\">",
"      Treiger BF, Humphrey LS, Peterson CV Jr, et al. Transesophageal echocardiography in renal cell carcinoma: an accurate diagnostic technique for intracaval neoplastic extension. J Urol 1991; 145:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/48\">",
"      Van Camp G, Abdulsater J, Cosyns B, et al. Transesophageal echocardiography of right atrial metastasis of a hepatocellular carcinoma. Chest 1994; 105:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/49\">",
"      Simonson JS, Schiller NB. Sonospirometry: a new method for noninvasive estimation of mean right atrial pressure based on two-dimensional echographic measurements of the inferior vena cava during measured inspiration. J Am Coll Cardiol 1988; 11:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31528/abstract/50\">",
"      Brennan JM, Blair JE, Goonewardena S, et al. Reappraisal of the use of inferior vena cava for estimating right atrial pressure. J Am Soc Echocardiogr 2007; 20:857.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5326 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31528=[""].join("\n");
var outline_f30_50_31528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11277353\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LEFT ATRIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      M-mode echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11277739\">",
"      - LA dimension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Two-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11277746\">",
"      - LA volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11277753\">",
"      - LA thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transesophageal echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Detection of thrombi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Thrombus in sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11278595\">",
"      - Left atrial masses and tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LEFT ATRIAL APPENDAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Left atrial appendage function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RIGHT ATRIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Right atrial thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Right atrial tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      VENA CAVA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11277353\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5326\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5326|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?40/12/41152\" title=\"diagnostic image 1\">",
"      M mode echo normal aorta and left atrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/4/44096\" title=\"diagnostic image 2\">",
"      2D and M mode parasternal short axis echo normal aortic root",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/54/16228\" title=\"diagnostic image 3\">",
"      2D TEE and M mode images parasternal short axis aortic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?3/4/3138\" title=\"diagnostic image 4\">",
"      Apical 2 chamber long axis LA volume by planimetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/28/26050\" title=\"diagnostic image 5\">",
"      TEE LA and LA appendage thrombi and spontaneous contrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/50/18223\" title=\"diagnostic image 6\">",
"      Spontaneous echo contrast seen in the left atrium on TEE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/55/26481\" title=\"diagnostic image 7\">",
"      Apical 4 chamber LA myxoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/28/38338\" title=\"diagnostic image 8\">",
"      Left atrial myxoma TTE TEE I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/53/34641\" title=\"diagnostic image 9\">",
"      Left atrial myxoma TTE TEE II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5326|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/0/30725\" title=\"figure 1\">",
"      M mode echo parasternal long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/35/9778\" title=\"figure 2\">",
"      Apical 4 chamber LA volume by planimetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/12/28867\" title=\"figure 3\">",
"      Measurement right atrial volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/15/31999\" title=\"figure 4\">",
"      Apical 4 chamber right atrial tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5326|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?4/11/4273\" title=\"movie 1\">",
"      2D TTE short axis LA appendage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?25/10/25775\" title=\"movie 2\">",
"      TEE LA thrombus and spontaneous echo contrast 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?10/61/11231\" title=\"movie 3\">",
"      TEE LA thrombus and spontaneous echo contrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?30/38/31343\" title=\"movie 4\">",
"      TEE LA and prosthetic MV thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?23/51/24383\" title=\"movie 5\">",
"      TEE LA appendage thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?4/61/5072\" title=\"movie 6\">",
"      TEE left atrial appendage thrombus and spontaneous echo contrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?2/22/2402\" title=\"movie 7\">",
"      TEE left atrial myxoma 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?34/44/35522\" title=\"movie 8\">",
"      TEE left atrial myxoma 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5326|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?5/31/5618\" title=\"waveform 1\">",
"      Doppler transmitral inflow pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?17/30/17891\" title=\"waveform 2A\">",
"      Doppler LA appendage flow during normal sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?40/57/41881\" title=\"waveform 2B\">",
"      Doppler LA appendage flow during atrial fib and atrial flutter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12266?source=related_link\">",
"      Mechanisms of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13610?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=related_link\">",
"      Role of echocardiography in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16615?source=related_link\">",
"      Supraventricular arrhythmias after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23146?source=related_link\">",
"      Three-dimensional echocardiography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_50_31529="Treatment of chronic pulmonary aspergillosis";
var content_f30_50_31529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of chronic pulmonary aspergillosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/50/31529/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/50/31529/contributors\">",
"     David W Denning, MBBS, FRCP, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/50/31529/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/50/31529/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/50/31529/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/50/31529/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/50/31529/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pulmonary aspergillosis includes several disease manifestations, including aspergilloma, chronic cavitary pulmonary aspergillosis, chronic fibrosing pulmonary aspergillosis, and chronic necrotizing aspergillosis (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    below). A duration of disease longer than three months distinguishes chronic pulmonary aspergillosis from acute and subacute pulmonary aspergillosis.",
"   </p>",
"   <p>",
"    The treatment of chronic pulmonary aspergillosis will be reviewed here. The pathophysiology, clinical manifestations, and diagnosis of chronic pulmonary aspergillosis are discussed separately; the treatment of allergic bronchopulmonary aspergillosis (ABPA) and invasive aspergillosis are also reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22408?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pulmonary aspergillosis describes several patterns of disease. However, the terminology that has been developed can be difficult to apply to a spectrum of disease entities that have considerable overlap and variation in severity. The following terminology will be used to describe the spectrum of disease; each entity is characterized by specific radiographic findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aspergilloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;An aspergilloma is a fungus ball composed of Aspergillus hyphae, fibrin, mucus, and cellular debris found within a pulmonary cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/2\">",
"     2",
"    </a>",
"    ]. Aspergillomas arise in preexisting pulmonary cavities that have become colonized with Aspergillus spp or develop in chronic cavitary pulmonary aspergillosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the aspergilloma is single, the cavity stable over months, and the patient has few symptoms (ie, a mild cough only) and little evidence of systemic inflammation, a simple aspergilloma may be diagnosed. We will use the term \"simple aspergilloma\" to distinguish this entity from the more complex forms of chronic pulmonary aspergillosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3913?source=see_link&amp;anchor=H1064486416#H1064486416\">",
"     \"Diagnosis of invasive aspergillosis\", section on 'Diagnostic modalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chronic cavitary pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term, \"chronic cavitary pulmonary aspergillosis,\" describes a pattern of disease in immunocompetent patients in whom there is formation and expansion of one or more pulmonary cavities over months (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54038 \" href=\"mobipreview.htm?31/11/31924\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65409 \" href=\"mobipreview.htm?39/30/40420\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77208 \" href=\"mobipreview.htm?24/12/24773\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56179 \" href=\"mobipreview.htm?15/42/16033\">",
"     image 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1\">",
"     1",
"    </a>",
"    ]. This term is preferred over the older term, \"complex aspergilloma,\" because more than 70 percent of such patients don't have an aspergilloma visible radiographically. Approximately 90 percent of patients with CCPA have Aspergillus IgG antibodies in the blood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22408?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of chronic pulmonary aspergillosis\", section on 'Radiographic features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22408?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations and diagnosis of chronic pulmonary aspergillosis\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic fibrosing pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic fibrosing pulmonary aspergillosis is a late-stage manifestation of chronic cavitary pulmonary aspergillosis in which progression to marked and extensive lung fibrosis has occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chronic necrotizing pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term, \"chronic necrotizing pulmonary aspergillosis,\" is best reserved for patients with some degree of immunocompromise who have a shorter duration of illness compared with patients with chronic cavitary pulmonary aspergillosis (eg, weeks rather than months) and in whom hyphal invasion of tissue is observed histologically, or can be inferred based upon radiographic findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1\">",
"     1",
"    </a>",
"    ]. Such patients usually have a single thin-walled cavity or area of cavitating",
"    <span class=\"nowrap\">",
"     pneumonia/consolidation",
"    </span>",
"    and may have detectable Aspergillus antigen (galactomannan) or Aspergillus IgG antibodies (precipitins) in blood. We favor the term \"subacute invasive pulmonary aspergillosis\" to describe this process since it represents a slowly progressive form of invasive aspergillosis; however, we will use the term \"chronic necrotizing pulmonary aspergillosis,\" since it is more widely recognized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since chronic pulmonary aspergillosis represents a spectrum of disease, and the risks and benefits of medical and surgical therapy vary with the manifestations of disease and the patient's pulmonary status, the approach to therapy must be individualized. Our recommendations are in keeping with those of the 2008 Infectious Diseases Society of America guidelines for the treatment of aspergillosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Aspergilloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the treatment of a simple aspergilloma are limited to extensive case series over decades and case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Surgical resection is offered in order to prevent or treat potentially life-threatening hemoptysis, and is usually curative. In patients with good respiratory function, no other significant contraindications to thoracotomy, and disease limited to one lobe, the 30 day operative mortality is &lt;5 percent and, in recent series, &lt;1 percent at centers that have substantial experience with this disease. Recurrent infection, inability to take azole therapy, azole resistance, and concurrent infection or tumor represent additional indications for surgical resection, but carry greater risk. Embolization is appropriate in selected patients, and may be used before surgery to stabilize the patient. Pre- and post-operative antifungal therapy (usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ) is appropriate to minimize the risk of post-operative pleural aspergillosis, in case the cavity is opened inadvertently during surgery, leading to spillage. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Surgery'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Embolization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Antifungal therapy provides limited benefit for the treatment of a simple aspergilloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. As an example, in a study that included 14 patients with aspergilloma who were treated with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    for an average of seven months (range 2 to 13 months), two patients were considered to be cured based upon the absence of symptoms and the development of scarring of the initial radiographic abnormalities; eight patients had significant clinical improvement despite a lack of radiographic improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/6\">",
"     6",
"    </a>",
"    ]. However, two patients had no clinical or radiographic response, and two patients had clinical and radiographic worsening. Instillation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    into a cavity has sometimes been effective. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Investigational approaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many patients, such as those who are asymptomatic and have stable radiographic findings over many months, require no therapy. However, progression to chronic cavitary pulmonary aspergillosis, sometimes with extensive fibrosis, is common and can occur silently, so continued observation is required. Spontaneous resolution of the aspergilloma occurs in fewer than 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Antifungal therapy for a single aspergilloma is reserved for patients with an indication for therapy who are unable to undergo surgery. The choice of antifungal agent is similar to that for chronic cavitary pulmonary aspergillosis, which is discussed below. Patients with incidentally resected Aspergillus nodules, initially thought to be carcinoma of the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/12\">",
"     12",
"    </a>",
"    ], should not receive antifungal therapy, but should be followed up with appropriate imaging and Aspergillus antibody titers for months or years to detect relapse of active infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chronic cavitary pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to patients with a simple aspergilloma, the vast majority of patients with chronic cavitary pulmonary aspergillosis and chronic fibrosing pulmonary aspergillosis require antifungal therapy. Only asymptomatic patients with radiographically and serologically stable disease, as determined over many months, do not require therapy. Embolization is indicated to prevent or treat hemoptysis. Surgical outcomes are not as good as those for single aspergillomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22408?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'Surgery'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Embolization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The evidence regarding the efficacy of long-term antifungal therapy for chronic cavitary pulmonary aspergillosis is based upon small case series and open-label non-comparative studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1,13-16\">",
"     1,13-16",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    are the preferred oral agents for the treatment of chronic pulmonary aspergillosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1,3,13-15,17\">",
"     1,3,13-15,17",
"    </a>",
"    ], with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    being substituted for failure, toxicity, or emergence of resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Choice of agent'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    has been used most commonly for the treatment of chronic pulmonary aspergillosis. Among 17 patients with chronic pulmonary aspergillosis, the majority of whom had chronic cavitary pulmonary aspergillosis, initial therapy with itraconazole resulted in improvement or stabilization of disease in 12 patients (71 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1\">",
"     1",
"    </a>",
"    ]. The duration of therapy ranged from 12 days to over 10 years. In a three-center prospective series of 29 patients, 44 percent responded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    has been studied in three prospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/19-21\">",
"     19-21",
"    </a>",
"    ], involving a total of 165 patients, as well as in older collected series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In a trial in France, 5 of 41 patients died on therapy, and 7 (17 percent) were intolerant of voriconazole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/20\">",
"     20",
"    </a>",
"    ]. The overall response rate at six months was 32 percent, with better responses in patients with chronic necrotizing pulmonary aspergillosis than in those with chronic cavitary pulmonary aspergillosis. In a multicenter study in Japan, 61 percent responded well, with only two patients stopping therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/21\">",
"     21",
"    </a>",
"    ]. IV voriconazole can be used in severely ill patients who are not suspected of having azole-resistant Aspergillus infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    was evaluated in a retrospective study of 67 patients with chronic pulmonary aspergillosis who were treated for at least six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/16\">",
"     16",
"    </a>",
"    ]. Clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic response to or stabilization of disease with posaconazole was observed in 61 percent of patients at six months and 46 percent of patients at 12 months. This suggests that posaconazole may have similar efficacy to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , although prospective trials are necessary to determine the optimal therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    or an echinocandin, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , should be used in severely ill patients who are failing azole therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1,19\">",
"     1,19",
"    </a>",
"    ]. Almost all reported studies with an echinocandin used micafungin. One study compared micafungin with IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    as initial therapy of chronic pulmonary aspergillosis in a randomized open-label trial, and noted similar response rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/19\">",
"     19",
"    </a>",
"    ]. A later prospective study of micafungin in 38 patients with chronic pulmonary aspergillosis suggested that the maximum useful dose of micafungin is 150 mg once daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/22\">",
"     22",
"    </a>",
"    ]. Another study compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    with micafungin with similar results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/23\">",
"     23",
"    </a>",
"    ]. Our own experience indicates that amphotericin B can also be effective for initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic fibrosing pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than antifungal therapy as discussed above, there are no specific additional treatments for chronic fibrosing pulmonary aspergillosis. Symptomatic remedies, rapid institution of antibiotics for intercurrent bacterial infections, oxygen, and adequate nutrition are all indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chronic necrotizing pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic necrotizing pulmonary aspergillosis, or subacute invasive pulmonary aspergillosis, is treated with antifungal agents in a similar fashion to invasive aspergillosis. Embolization may be indicated for certain patients to treat hemoptysis. Surgical resection is not usually contemplated because of the patient's general state of health and poor respiratory reserve. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Surgery'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Embolization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast to patients with acute invasive aspergillosis, nearly all patients with chronic necrotizing pulmonary aspergillosis can use an oral antifungal agent at the start of therapy although loading doses and therapeutic monitoring are indicated. There is a greater experience with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , but",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    has become the preferred antifungal agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data regarding the efficacy of antifungal agents for chronic necrotizing pulmonary aspergillosis are based on small non-randomized open-label studies and case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/3,6,13,15,24\">",
"     3,6,13,15,24",
"    </a>",
"    ]. In one study of chronic necrotizing pulmonary aspergillosis, 14 patients were treated with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and a complete or partial response was noted in 13 patients (93 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/6\">",
"     6",
"    </a>",
"    ]. However, three patients experienced relapse after discontinuation of therapy.",
"   </p>",
"   <p>",
"    In a prospective open-label study of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    in 21 patients with chronic necrotizing pulmonary aspergillosis, a complete or partial response was observed in nine patients (43 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/15\">",
"     15",
"    </a>",
"    ]. A subsequent retrospective study found that 10 of 15 patients (67 percent) who had with chronic necrotizing pulmonary aspergillosis and who received voriconazole had radiographic and clinical improvement, and 8 of 13 (62 percent) were considered to have control of disease after a median of 10 months (range 6 to 36 months) of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/13\">",
"     13",
"    </a>",
"    ]. Finally, an open label study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    included nine patients with chronic necrotizing pulmonary aspergillosis, of whom six had a favorable clinical response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANTIFUNGAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The azoles, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , are the mainstays of antifungal therapy for chronic pulmonary aspergillosis. The efficacy of and indications for antifungal therapy are discussed above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Approach to therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is important to be aware that significant adverse effects and drug interactions commonly occur with the azoles and that monitoring of serum concentrations is necessary. Potential drug interactions, especially those related to cytochrome P450, are important since many patients who require long-term therapy for chronic pulmonary aspergillosis are receiving other agents that may cause significant interactions. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2140877\">",
"    <span class=\"h3\">",
"     Oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When oral antifungal therapy is indicated, we would recommend either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg twice daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (200 mg twice daily) as first-line agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/3\">",
"     3",
"    </a>",
"    ]. The majority of accumulated clinical experience has been with itraconazole, but voriconazole has similar activity against Aspergillus spp, is better tolerated in some patients, and also appears to be effective for the treatment of chronic pulmonary aspergillosis. The decision as to which agent to use should be based on tolerability, costs, and possible drug interactions. The efficacy of these agents is discussed above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Approach to therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is increasing experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    for chronic pulmonary aspergillosis. It is used in patients who have experienced failure, toxicity, or emergence of resistance with another regimen. Posaconazole solution is used in a dose of 400 mg twice daily with a fatty meal. There is no intravenous formulation of posaconazole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2140884\">",
"    <span class=\"h3\">",
"     Intravenous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In severely ill patients, or those infected with pan-azole resistant isolates, intravenous therapy is indicated. The choices are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (unless resistance is present), an echinocandin such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/19\">",
"     19",
"    </a>",
"    ]. Voriconazole at a dosage of 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for two doses on the first day followed by 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily thereafter, micafungin at a dosage of 150 mg daily, or amphotericin B can be used. The amphotericin B deoxycholate dosage is 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily, but many clinicians prefer to use a less nephrotoxic lipid formulation at a dosage of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily.",
"   </p>",
"   <p>",
"    Echinocandins appear to be useful in patients with chronic pulmonary aspergillosis who are failing therapy due to azole resistance or who are intolerant of other drugs. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Chronic cavitary pulmonary aspergillosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Chronic necrotizing pulmonary aspergillosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Clinical failure'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic cavitary and chronic fibrosing pulmonary aspergillosis probably require lifelong antifungal therapy. Data are limited, but relapse is common if treatment is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Discontinuation of therapy is usually associated with gradual return of symptoms, worsening of findings by chest radiography, and rising Aspergillus antibody titers (precipitins).",
"   </p>",
"   <p>",
"    The duration of antifungal therapy in patients who undergo surgical resection is discussed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Assessing treatment response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response to antifungal therapy can be assessed by reviewing pulmonary symptoms (cough, sputum production, dyspnea), systemic symptoms, and change in weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1,13,14\">",
"     1,13,14",
"    </a>",
"    ]. Symptoms usually improve during the first six to eight weeks of therapy, and a lack of improvement by 12 weeks can be classified as a failure. Assessment of response is more complex in those with multiple pulmonary pathologies, and require appropriate assessment and experienced clinical judgment. We have found the St George&rsquo;s Respiratory Questionnaire to be superior to the general health survey, SF36, in assessing severity of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/26\">",
"     26",
"    </a>",
"    ] and in assessing therapeutic response.",
"   </p>",
"   <p>",
"    Falling Aspergillus antibody titer (precipitins) is the most useful laboratory parameter to follow, but takes months to change. Inflammatory markers, such as C-reactive protein",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erythrocyte sedimentation rate, fall when therapy is successful, but slowly, and incompletely. The frequency with which laboratory and radiographic tests should be monitored during therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22408?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical manifestations and diagnosis of chronic pulmonary aspergillosis\", section on 'Monitoring during therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On chest imaging, pericavitary infiltrates and pleural thickening adjacent to cavities appear to be indicative of disease activity; these abnormalities may improve with appropriate antifungal therapy, leaving residual thin-walled empty cavities. The cavities themselves usually stabilize in size in response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22408?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of chronic pulmonary aspergillosis\", section on 'Radiographic features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lack of resolution of hemoptysis may reflect either antifungal failure or persistence of a large vascular network that would not be expected to resolve with antifungal control of the fungal infection alone. Recurrence of hemoptysis may be a sign of antifungal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral azole therapy is associated with response rates of approximately 60 to 80 percent, depending on the azole, drug concentrations, susceptibility of the organism, and probably some immune parameters that are not well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1,6,13-16,19,27\">",
"     1,6,13-16,19,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who fail oral therapy or who are very ill with extensive disease may require a two to four week course of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/25\">",
"     25",
"    </a>",
"    ]. Maintenance of improved health on oral azoles is then often achievable, even if therapeutic failure with initial azole therapy was documented.",
"   </p>",
"   <p>",
"    Glucocorticoids at modest doses should be used with caution in patients with chronic pulmonary aspergillosis, especially early in the treatment course before antifungal response can be assessed, but may have a place in management for some patients who remain chronically ill, but have evidence of control of Aspergillus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/28\">",
"     28",
"    </a>",
"    ]. Occasional patients appear to decompensate with markedly increased breathlessness and reduced DLCO after starting antifungal therapy; oral glucocorticoids may be useful in such patients.",
"   </p>",
"   <p>",
"    There are at least four well recognized reasons for clinical failure of therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Low serum concentration of azole",
"      </strong>",
"      &mdash; The variable bioavailability of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      present a challenge to clinicians that is best resolved by therapeutic drug monitoring. Low serum concentrations may be the result of poor absorption, inappropriate timing of medication with food, rapid metabolism due to drug-drug interactions, a switch in capsule formulation to a generic variety, or poor adherence.",
"      <br/>",
"      <br/>",
"      In most circumstances in which low plasma itraconazole levels occur, altering the formulation, improving the timing of the dose with food, and removing interacting drugs allows adequate serum concentrations to be achieved. If this strategy is not successful, raising the itraconazole dose to 200 mg three times daily is usually successful. Generic preparations of itraconazole, available in some countries, have variable bioavailability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/29\">",
"       29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      With voriconazole, care should be taken with dose escalation, since resulting changes in plasma level may be disproportionately higher than dosage increments due to non-linear pharmacokinetics. Low posaconazole serum concentrations may reflect poor food intake; changing the dose to 200 mg four times per day and increasing fatty food intake with treatment may be helpful. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Choice of agent'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link&amp;anchor=H26#H26\">",
"       \"Pharmacology of azoles\", section on 'Serum drug concentration monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Antifungal resistance",
"      </strong>",
"      &mdash; Resistance to one or more azoles may occur during long-term treatment, and may even occur in the absence of antifungal therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/30\">",
"       30",
"      </a>",
"      ]. Low concentrations of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      probably predispose to itraconazole resistance and possibly to azole cross-resistance. A positive culture while on antifungal therapy is an indication for susceptibility testing, or if not possible, then a switch of therapy. Itraconazole resistance is considerably more common than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      resistance. Itraconazole-resistant Aspergillus isolates obtained after itraconazole treatment may be cross-resistant to voriconazole, but usually are not. Itraconazole-resistant isolates may have slightly elevated minimum inhibitory concentrations to posaconazole.",
"      <br/>",
"      <br/>",
"      In patients who are failing azole therapy, treatment decisions should be guided by in vitro susceptibility results. Isolates with MICs &ge;4",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      to either itraconazole or voriconazole are very unlikely to respond to either of these agents. Isolates with a posaconazole MIC &ge;1",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      are very unlikely to respond to posaconazole [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/16,31\">",
"       16,31",
"      </a>",
"      ]. Some isolates resistant to all azoles require a switch to long-term",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (usually a lipid formulation) or an echinocandin, since azole-resistant isolates are not cross-resistant to members of other antifungal classes. Antifungal resistance among Aspergillus species is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/21/29018?source=see_link\">",
"       \"Antifungal susceptibility testing\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link&amp;anchor=H458851271#H458851271\">",
"       \"Treatment and prevention of invasive aspergillosis\", section on 'Antifungal resistance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Coinfection with another pathogen",
"      </strong>",
"      &mdash; Nontuberculous mycobacterial infections may precede or follow chronic cavitary pulmonary aspergillosis. If this occurs,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      should be avoided, if possible, because of induction of azole metabolism resulting in lowering of serum azole concentrations. Combinations of an azole, a fluoroquinolone,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a macrolide may prolong the QT interval, which should be monitored. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=see_link\">",
"       \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"       \"Pharmacology of azoles\", section on 'Drug interactions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1514?source=see_link&amp;anchor=H22#H22\">",
"       \"Azithromycin, clarithromycin, and telithromycin\", section on 'Long QT syndrome'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Many patients with chronic cavitary pulmonary aspergillosis have bronchiectasis, producing voluminous amounts of purulent sputum, which may be the result of the fungal infection itself or a superimposed bacterial infection. Antibiotic therapy against this pathogen is indicated. When a cavity becomes superinfected with bacteria, such as Pseudomonas aeruginosa, a fluid level may appear. If sputum cultures do not yield a pathogen, percutaneous aspiration and drainage of such a cavity may be required, accompanied by antibiotic therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24729?source=see_link\">",
"       \"Lung abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Interferon gamma production defect",
"      </strong>",
"      &mdash; Numerous relatively subtle immune defects are seen in chronic cavitary pulmonary aspergillosis patients, but the one remediable one is interferon gamma deficiency. Testing in some patients shows defective production to standard stimuli [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/32\">",
"       32",
"      </a>",
"      ]. A replacement dose of interferon gamma (50 to 100 mcg subcutaneously three times per week at night) makes a substantial difference to some patients. Three patients without known defects in interferon gamma production had stable or improved disease when interferon gamma was given in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1\">",
"       1",
"      </a>",
"      ]. Likewise, two patients with poor interferon gamma production also benefited [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/32\">",
"       32",
"      </a>",
"      ]. Further studies are needed to establish the role of interferon gamma treatment in such individuals, and the optimal dose and frequency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4297?source=see_link\">",
"       \"Mendelian susceptibility to mycobacterial diseases (MSMD)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF HEMOPTYSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the mainstay of treatment for symptomatic patients with simple aspergillomas in order to prevent or treat life-threatening hemoptysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/3\">",
"     3",
"    </a>",
"    ], or to remove disease and try to effect a cure. Surgery is generally well-tolerated in patients with a single aspergilloma, with a mortality rate of &lt;1 percent in multiple contemporary studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/4,5,33-36\">",
"     4,5,33-36",
"    </a>",
"    ]. However, patients with more complicated disease, such as those with chronic cavitary pulmonary aspergillosis or pleural-based aspergillomas, are more likely to have complications, and usually surgery is avoided. As an example, among 89 patients who underwent surgical resection for aspergilloma, no deaths or complications occurred in patients with asymptomatic disease, but five postoperative deaths occurred in patients with complicated disease, all of whom had undergone lobectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/33\">",
"     33",
"    </a>",
"    ]. Surgical and anesthetic advances have improved outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with chronic cavitary pulmonary aspergillosis, surgical removal of aspergillomas is fraught with difficulty because of the very vascular, adherent pleura and because the remaining chest cavity may become infected with Aspergillus spp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/37\">",
"     37",
"    </a>",
"    ]. Surgical removal of pleural-based aspergillomas, in particular, is prone to many complications and should be avoided if possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/38\">",
"     38",
"    </a>",
"    ]. Many patients have underlying respiratory insufficiency and removal of a lobe of the lung would leave them with inadequate pulmonary reserve. However, several series describe acceptable outcomes with 2 to 5 percent mortality and ~25 percent complication rate overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/34,35,39-41\">",
"     34,35,39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In unilateral chronic cavitary pulmonary aspergillosis, with or without an aspergilloma, surgery may be preferable to long-term antifungal therapy for some patients with limited disease, azole resistance,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drug intolerance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not studied, we suggest administering antifungal therapy before and immediately after surgery. The optimal agent is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , because of its intrinsic activity, and the availability of both oral and IV formulations. Voriconazole should be given orally as 400 mg twice daily for the first day followed by 200 mg twice daily one or two weeks prior to surgery, if possible. If the aspergilloma was fully resected without spillage of the contents of the cavity into the pleura, then a four week course of voriconazole post-operatively is reasonable. If there is spillage, then a minimum of 12 weeks therapy is recommended in an attempt to prevent pleural aspergillosis. Fungal cultures should be obtained during surgery and susceptibility testing performed on isolates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/21/29018?source=see_link\">",
"     \"Antifungal susceptibility testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with moderate or severe hemoptysis who are too ill to undergo surgery or have extensive disease, embolization may be appropriate. Most instances of hemoptysis are caused by abnormal and novel vascular connections to the systemic circulation in proximity to the affected area (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54038 \" href=\"mobipreview.htm?31/11/31924\">",
"     image 1",
"    </a>",
"    ). Usually this is the bronchial circulation but it may be any of the other arteries supplying the chest (eg, intercostal, subclavian, or internal mammary arteries). Otherwise asymptomatic patients with aspergillomas may have an extensive network of small vessels and can develop hemoptysis. Several abnormal connections may exist in a single patient. The objective of embolization is to permanently occlude these vessels.",
"   </p>",
"   <p>",
"    Patients with a communication between an intercostal and the anterior spinal artery can only be embolized safely if the catheter is introduced well past the anterior spinal artery. These patients require a skilled interventional radiologist, and the patient has to lie supine for 2 to 4 hours during the procedure.",
"   </p>",
"   <p>",
"    Depending on the radiologist, approximately 50 to 90 percent of embolization procedures are successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. However, relapse has occurred in approximately 50 percent of patients; relapse can be minimized with successful long-term antifungal therapy. Complications include local pain, stroke, chest wall or spinal cord infarction, as well as reactions to the contrast dye. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Investigational approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary relief of hemoptysis may be gained with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    (typically 500 mg three times daily), although it is not licensed for this indication. It is widely used throughout the UK for hemoptysis. Tranexamic acid increases infarction potential, and a low rate of strokes has been reported after its use. It may not be well tolerated, with gastrointestinal upset being the most common adverse effect.",
"   </p>",
"   <p>",
"    The use of CT-guided intracavitary instillation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    has been attempted in some patients with inoperable aspergillomas. In one report, this procedure was performed in 40 inoperable cases of hemoptysis due to aspergilloma; the aspergilloma disappeared in 23 cases and the cavity also disappeared in three [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/45\">",
"     45",
"    </a>",
"    ]. Daily instillation of amphotericin B (50 mg in 20 mL dextrose) into a cavity through a catheter benefited some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/46\">",
"     46",
"    </a>",
"    ]. Spillage of amphotericin B into the bronchial tree can be problematic for patients with poor respiratory reserve. Repeated installations are often required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/47\">",
"     47",
"    </a>",
"    ], and efficacy has not been proven in randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients are not able to take antifungal therapy because of adverse events, antifungal resistance, or personal preference. In such patients, adequate nutrition to maintain weight, avoidance or treatment of depression, and oxygen for hypoxic patients are helpful. In those with recurrent or continuous infection (bronchiectasis), intermittent or long term antibiotic therapy is often helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no useful natural history data on patients who have simple aspergillomas, separable from those who have undergone surgical resection and those with other forms of chronic pulmonary aspergillosis. Taken together, and not including chronic necrotizing pulmonary aspergillosis, an annual 6 percent mortality was noted in those who developed aspergillosis after tuberculosis over four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of chronic cavitary pulmonary aspergillosis with and without antifungal therapy can be summarized as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High initial mortality of 30 percent over three to six months",
"     </li>",
"     <li>",
"      Approximately 40 percent mortality at three years",
"     </li>",
"     <li>",
"      Approximately 60 to 80 percent mortality at seven years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Few data are available with regard to the prognosis of chronic fibrosing pulmonary aspergillosis, but it is almost certainly worse than chronic cavitary pulmonary aspergillosis, with most deaths occurring from sepsis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacterial pneumonia with respiratory failure.",
"   </p>",
"   <p>",
"    One small series noted a much worse outcome in patients with sarcoidosis with chronic pulmonary aspergillosis than those with prior tuberculosis for unclear reasons, but possibly related to glucocorticoid use in the former group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of antifungal therapy on longevity has not been documented, but our own experience is more favorable than that published before orally active agents for aspergillosis became available in 1991. Current estimates are an annual mortality rate of 5 to 7 percent in patients receiving antifungal therapy, mostly as a result of pneumonia leading to acute respiratory failure.",
"   </p>",
"   <p>",
"    Some patients develop carcinoma of the lung in immediate proximity to the infected area, which is problematic for both diagnosis and treatment and is usually inoperable and ultimately fatal.",
"   </p>",
"   <p>",
"    Chronic necrotizing pulmonary aspergillosis is associated with high mortality as demonstrated by a 20 percent short-term mortality rate despite treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/52\">",
"     52",
"    </a>",
"    ], a 33 percent three month mortality rate, and a 51 percent mortality rate over a median of 15 months, also despite treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31529/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/6/31842?source=see_link\">",
"       \"Patient information: Chronic pulmonary aspergillosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic pulmonary aspergillosis includes several disease manifestations, including aspergilloma, chronic cavitary pulmonary aspergillosis, chronic fibrosing pulmonary aspergillosis, and chronic necrotizing aspergillosis. A duration of disease longer than three months distinguishes chronic pulmonary aspergillosis from acute and subacute pulmonary aspergillosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic pulmonary aspergillosis represents a spectrum of disease; the risks and benefits of medical and surgical therapy vary with the manifestations of disease and the patient's pulmonary status, and thus, the approach to therapy must be individualized. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a simple aspergilloma, we suggest surgical resection for patients who are symptomatic, particularly for those with hemoptysis, in order to prevent or treat potentially life-threatening hemoptysis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest antifungal therapy for patients who have progressive radiographic findings",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms and who are unable to undergo surgery. We also suggest antifungal agents for adjunctive therapy following surgical resection, particularly if there is concern about concomitant tissue invasion by Aspergillus spp (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Approach to therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with moderate or severe hemoptysis who are too ill to undergo surgery or have extensive disease, embolization may be appropriate. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not treating asymptomatic patients who have a simple aspergilloma that is radiographically stable (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Aspergilloma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with chronic cavitary pulmonary aspergillosis or chronic fibrosing pulmonary aspergillosis, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      initially (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Voriconazole should be administered as 400 mg orally twice daily for the first day followed by 200 mg twice daily. Itraconazole should be administered as 200 mg orally twice daily. Serum drug concentrations should be monitored initially to optimize dose and preparation. Lifelong therapy is often required. For those who are severely ill, intravenous therapy may be needed initially. Voriconazole (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily for the first day followed by 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily thereafter),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      (150 mg daily), or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for a lipid formulation or 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for the deoxycholate formulation) can be used. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with chronic necrotizing pulmonary aspergillosis, which is more aggressive in its course than chronic cavitary pulmonary aspergillosis, we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (400 mg orally twice daily for the first day followed by 200 mg twice daily) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       Posaconazole",
"      </a>",
"      (400 mg orally twice daily),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      can be used as alternatives if the patient cannot take voriconazole. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/1\">",
"      Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37 Suppl 3:S265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/2\">",
"      Judson MA, Stevens DA. The treatment of pulmonary aspergilloma. Curr Opin Investig Drugs 2001; 2:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/3\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/4\">",
"      Lejay A, Falcoz PE, Santelmo N, et al. Surgery for aspergilloma: time trend towards improved results? Interact Cardiovasc Thorac Surg 2011; 13:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/5\">",
"      Chen QK, Jiang GN, Ding JA. Surgical treatment for pulmonary aspergilloma: a 35-year experience in the Chinese population. Interact Cardiovasc Thorac Surg 2012; 15:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/6\">",
"      Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990; 23:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/7\">",
"      De Beule K, De Doncker P, Cauwenbergh G, et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses 1988; 31:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/8\">",
"      Lebeau B, Pelloux H, Pinel C, et al. Itraconazole in the treatment of aspergillosis: a study of 16 cases. Mycoses 1994; 37:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/9\">",
"      Campbell JH, Winter JH, Richardson MD, et al. Treatment of pulmonary aspergilloma with itraconazole. Thorax 1991; 46:839.",
"     </a>",
"    </li>",
"    <li>",
"     Denning, DW. Chronic aspergillosis. In: Aspergillus fumigatus and Aspergillosis. Latge, JP, Steinbach, WJ (Eds). ASM Press, Washington, DC, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/11\">",
"      Hammerman KJ, Christianson CS, Huntington I, et al. Spontaneous lysis of aspergillomata. Chest 1973; 64:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/12\">",
"      Baxter CG, Bishop P, Low SE, et al. Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography. Thorax 2011; 66:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/13\">",
"      Camuset J, Nunes H, Dombret MC, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 2007; 131:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/14\">",
"      Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 2006; 52:e133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/15\">",
"      Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006; 119:527.e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/16\">",
"      Felton TW, Baxter C, Moore CB, et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 2010; 51:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/17\">",
"      Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/18\">",
"      Yoshida K, Kurashima A, Kamei K, et al. Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study. J Infect Chemother 2012; 18:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/19\">",
"      Kohno S, Izumikawa K, Ogawa K, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 2010; 61:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/20\">",
"      Cadranel J, Philippe B, Hennequin C, et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis 2012; 31:3231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/21\">",
"      Saito T, Fujiuchi S, Tao Y, et al. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Infection 2012; 40:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/22\">",
"      Kohno S, Izumikawa K, Kakeya H, et al. Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study. Med Mycol 2011; 49:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/23\">",
"      Kohno S, Izumikawa K, Yoshida M, et al. A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis 2013; 32:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/24\">",
"      Caras WE, Pluss JL. Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Mayo Clin Proc 1996; 71:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/25\">",
"      Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/26\">",
"      Al-shair K, Atherton GTW, Kennedy D, et al. Validity and reliability of the St. George&rsquo;s Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis. Chest 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/27\">",
"      Tsubura E. [Multicenter clinical trial of itraconazole in the treatment of pulmonary aspergilloma. Pulmonary Aspergilloma Study Group]. Kekkaku 1997; 72:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/28\">",
"      Hafeez I, Muers MF, Murphy SA, et al. Non-tuberculous mycobacterial lung infection complicated by chronic necrotising pulmonary aspergillosis. Thorax 2000; 55:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/29\">",
"      Pasqualotto AC, Denning DW. Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. Int J Antimicrob Agents 2007; 30:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/30\">",
"      Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/31\">",
"      Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009; 12:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/32\">",
"      Kelleher P, Goodsall A, Mulgirigama A, et al. Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis. Eur Respir J 2006; 27:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/33\">",
"      Regnard JF, Icard P, Nicolosi M, et al. Aspergilloma: a series of 89 surgical cases. Ann Thorac Surg 2000; 69:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/34\">",
"      Kim YT, Kang MC, Sung SW, Kim JH. Good long-term outcomes after surgical treatment of simple and complex pulmonary aspergilloma. Ann Thorac Surg 2005; 79:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/35\">",
"      Pratap H, Dewan RK, Singh L, et al. Surgical treatment of pulmonary aspergilloma: a series of 72 cases. Indian J Chest Dis Allied Sci 2007; 49:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/36\">",
"      Brik A, Salem AM, Kamal AR, et al. Surgical outcome of pulmonary aspergilloma. Eur J Cardiothorac Surg 2008; 34:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/37\">",
"      Daly RC, Pairolero PC, Piehler JM, et al. Pulmonary aspergilloma. Results of surgical treatment. J Thorac Cardiovasc Surg 1986; 92:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/38\">",
"      Massard, G, Roeslin, N, Wihlm, JM, et al. Surgical treatment of pulmonary and bronchial aspergilloma. Ann Chirurgie 1993; 47:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/39\">",
"      Lee JG, Lee CY, Park IK, et al. Pulmonary aspergilloma: analysis of prognosis in relation to symptoms and treatment. J Thorac Cardiovasc Surg 2009; 138:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/40\">",
"      Shiraishi Y, Katsuragi N, Nakajima Y, et al. Pneumonectomy for complex aspergilloma: is it still dangerous? Eur J Cardiothorac Surg 2006; 29:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/41\">",
"      Demir A, Gunluoglu MZ, Turna A, et al. Analysis of surgical treatment for pulmonary aspergilloma. Asian Cardiovasc Thorac Ann 2006; 14:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/42\">",
"      Jardin M, Remy J. Control of hemoptysis: systemic angiography and anastomoses of the internal mammary artery. Radiology 1988; 168:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/43\">",
"      Swanson KL, Johnson CM, Prakash UB, et al. Bronchial artery embolization : experience with 54 patients. Chest 2002; 121:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/44\">",
"      Corr P. Management of severe hemoptysis from pulmonary aspergilloma using endovascular embolization. Cardiovasc Intervent Radiol 2006; 29:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/45\">",
"      Giron J, Poey C, Fajadet P, et al. CT-guided percutaneous treatment of inoperable pulmonary aspergillomas: a study of 40 cases. Eur J Radiol 1998; 28:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/46\">",
"      Kravitz1 JN, Berry2 MW, Schabel2 SI, Judson3 MA. A Modern Series of Percutaneous Intracavitary Instillation of Amphotericin B for the treatment of Severe Hemoptysis from Pulmonary Aspergilloma*. Chest 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/47\">",
"      Lee KS, Kim HT, Kim YH, Choe KO. Treatment of hemoptysis in patients with cavitary aspergilloma of the lung: value of percutaneous instillation of amphotericin B. AJR Am J Roentgenol 1993; 161:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/48\">",
"      Aspergilloma and residual tuberculous cavities--the results of a resurvey. Tubercle 1970; 51:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/49\">",
"      Jewkes, J, Kay, PH, Paneth, M, Citron, KM. Pulmonary aspergilloma: analysis of cavitating invasive pulmonary aspergillosis in immunocompromised patients. Ann Thorac Surg 1983; 53: 621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/50\">",
"      Tomlinson JR, Sahn SA. Aspergilloma in sarcoid and tuberculosis. Chest 1987; 92:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/51\">",
"      Ohba H, Miwa S, Shirai M, et al. Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med 2012; 106:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31529/abstract/52\">",
"      Binder RE, Faling LJ, Pugatch RD, et al. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore) 1982; 61:109.",
"     </a>",
"    </li>",
"    <li>",
"     Nam, HS, Jeon, K, Um, SW, et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis 2009; [Epub ahead of print].",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2440 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31529=[""].join("\n");
var outline_f30_50_31529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aspergilloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chronic cavitary pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic fibrosing pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chronic necrotizing pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Aspergilloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chronic cavitary pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic fibrosing pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chronic necrotizing pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANTIFUNGAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2140877\">",
"      - Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2140884\">",
"      - Intravenous therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Assessing treatment response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT OF HEMOPTYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Investigational approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2440\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2440|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/11/31924\" title=\"diagnostic image 1\">",
"      CPA radiograph and angiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/30/40420\" title=\"diagnostic image 2\">",
"      CPA radiograph and CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/12/24773\" title=\"diagnostic image 3\">",
"      CPA radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/42/16033\" title=\"diagnostic image 4\">",
"      CPA radiograph",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/21/29018?source=related_link\">",
"      Antifungal susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22408?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24729?source=related_link\">",
"      Lung abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4297?source=related_link\">",
"      Mendelian susceptibility to mycobacterial diseases (MSMD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/6/31842?source=related_link\">",
"      Patient information: Chronic pulmonary aspergillosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_50_31530="Clinical manifestations and natural history of chronic hepatitis C virus infection";
var content_f30_50_31530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and natural history of chronic hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/50/31530/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/50/31530/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/50/31530/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/50/31530/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/50/31530/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/50/31530/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/50/31530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with the hepatitis C virus (HCV) can result in both acute and chronic hepatitis. The acute process is most often asymptomatic; if symptoms are present, they usually abate within a few weeks. Acute infection rarely causes hepatic failure.",
"   </p>",
"   <p>",
"    Acute HCV typically leads to chronic infection; 60 to 80 percent of cases develop chronic hepatitis (abnormal liver enzymes). Chronic HCV infection is usually slowly progressive and may not result in clinically apparent liver disease in many patients if the infection is acquired later in life. Approximately 20 to 30 percent of chronically infected individuals develop cirrhosis over a 20- to 30-year period of time. Chronic HCV is the most common cause of chronic liver disease and the most frequent indication for liver transplantation in the United States.",
"   </p>",
"   <p>",
"    This topic will review the clinical features associated with chronic HCV infection and factors associated with the progression of chronic liver disease. Acute HCV and the epidemiology, diagnosis, and treatment of chronic HCV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=see_link\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK OF CHRONIC INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of chronic infection after an acute episode of hepatitis C is high. In most studies, 80 to 100 percent of patients remain HCV RNA positive, and 60 to 80 percent have persistently elevated liver enzymes (",
"    <a class=\"graphic graphic_figure graphicRef70891 \" href=\"mobipreview.htm?10/61/11229\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, for example, 142 HCV antibody-negative patients with a history of intravenous drug use were prospectively monitored for HCV seroconversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/3\">",
"     3",
"    </a>",
"    ]. During eight years of follow-up, seroconversion was documented in 43 (30 percent). HCV RNA clearance occurred in only six of the patients (14 percent) who seroconverted by antibody testing; the median time to HCV RNA clearance was 19 months (range 14 to 45).",
"   </p>",
"   <p>",
"    The mechanism responsible for the high prevalence of chronic infection is unclear. It may be related to the genetic diversity of the virus and its tendency toward rapid mutation, allowing HCV to escape immune recognition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29780?source=see_link\">",
"     \"Characteristics of the hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Host factors may also be involved in the ability to spontaneously clear the virus. One of the most influential factors appears to be certain polymorphisms of a site close to the interleukin-28B (IL28B) gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In one report of 1008 patients, the presence of the",
"    <span class=\"nowrap\">",
"     C/C",
"    </span>",
"    type allele was associated with clearance rates of approximately 50 to 55 percent compared with only 16 to 20 percent in patients with the",
"    <span class=\"nowrap\">",
"     T/T",
"    </span>",
"    type allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/6\">",
"     6",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     C/C",
"    </span>",
"    type alleles were more common in patients of European ancestry compared with those of African ancestry. A second study that included 284 patients with chronic HCV infection and 69 patients who had spontaneously cleared the virus found that the",
"    <span class=\"nowrap\">",
"     C/C",
"    </span>",
"    type allele was present in 73 percent of patients who spontaneously cleared the virus, compared with 46 percent of patients with persistent infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/9\">",
"     9",
"    </a>",
"    ]. These polymorphisms are also an important predictor of response during treatment with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link&amp;anchor=H16092947#H16092947\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'IL28B polymorphisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blacks are less likely than whites to have the",
"    <span class=\"nowrap\">",
"     C/C",
"    </span>",
"    type allele, and data suggest they may be less likely to spontaneously clear the virus. In a population-based study, 9 percent of blacks and 27 percent of whites where anti-HCV positive and HCV RNA negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/10\">",
"     10",
"    </a>",
"    ]. However, a limitation of the study is that information on which patients received treatment was not available, so these numbers likely overestimate the rate of spontaneous clearance.",
"   </p>",
"   <p>",
"    A number of other factors have also been implicated:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of specific HLA-DRB1 and DQB1 alleles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      High titers of neutralizing antibodies against HCV structural proteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Host neutralizing responses that target viral entry after HCV binding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The persistence of an HCV-specific CD4 T-cell response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      White patients with relatively low peak levels of HCV viremia during acute infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Female intravenous drug users had higher spontaneous clearance rates than males in one report [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Furthermore, lower rates of chronic infection have been reported after exposure in some populations. As an example, only 55 percent of a cohort of Irish women who had been infected after Rh immunization had HCV RNA detectable in serum (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/19\">",
"     19",
"    </a>",
"    ]. Children also appear to have a relatively low rate of developing chronic infection after exposure. In one study that included 67 children who developed HCV antibodies after receiving contaminated blood transfusions, only 37 (55 percent) had HCV RNA in blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with chronic infection are asymptomatic or have only mild nonspecific symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/21\">",
"     21",
"    </a>",
"    ]. The most frequent complaint is fatigue; other less common manifestations include nausea, anorexia, myalgia, arthralgia, weakness, and weight loss. The symptoms are rarely incapacitating and may be difficult to ascribe to liver disease alone (rather than to another illness such as depression); nevertheless, they may lead to a decrease in the quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], which may in part be accounted for by awareness of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/24\">",
"     24",
"    </a>",
"    ], and which can be improved following successful treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     Ondansetron",
"    </a>",
"    (a 5-HT3 receptor antagonist) 4 mg twice daily significantly improved fatigue in a placebo-controlled trial involving 36 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/26\">",
"     26",
"    </a>",
"    ]. The rationale for its use was based upon the observation that serotonin is associated with fatigue in animal and human models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/27\">",
"     27",
"    </a>",
"    ]. Long-term efficacy is unclear and treatment may be associated with constipation and cardiac arrhythmias. Fatigue improves in some patients who have a sustained virologic response following interferon-based therapy; in one of the largest series addressing this issue, fatigue improved in 29 of 83 responders versus 75 of 348 nonresponders (35 versus 22 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms of chronic HCV infection do not reliably reflect disease activity. One study, for example, evaluated a cohort of over 100 patients with chronic HCV infection and no clinical signs of cirrhosis who participated in two clinical studies at the National Institutes of Health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/29\">",
"     29",
"    </a>",
"    ]. Self-administered symptom scores were compared with those from 100 healthy blood donors without HCV. Fatigue was the most common complaint among both groups and occurred with similar frequency (62 percent in those with HCV versus 70 percent of controls). Abdominal pain, itching, and dark urine were the only complaints that were significantly more common among the HCV group, although they were present in only a small number of patients.",
"   </p>",
"   <p>",
"    The lack of correlation between the symptoms of HCV infection and either the serum ALT concentration or liver histology has been confirmed in other reports; however, symptoms appear to be more common once cirrhosis develops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HCV infection has been associated with cognitive impairment, which has been demonstrated in patients with HCV independent of the severity of liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. The mechanisms leading to the impairment are not well understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SERUM AMINOTRANSFERASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is wide variability in serum aminotransferase concentrations among individual patients with chronic HCV infection over time. Up to one-third of patients have a normal serum ALT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/2,34\">",
"     2,34",
"    </a>",
"    ]. Slight enzyme elevations are usually seen in the remaining patients; only about 25 percent have a serum ALT concentration more than twice normal, and it is rare to find elevations more than 10 times normal.",
"   </p>",
"   <p>",
"    There is generally a poor correlation between aminotransferase levels and liver histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. As an example, a study of 90 patients with chronic hepatitis C found no correlation between histologic findings and serum ALT values unless the ALT was elevated more than 10-fold; these marked elevations were associated with periportal inflammation and necrosis (so-called piecemeal necrosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/35\">",
"     35",
"    </a>",
"    ]. The mean values of aminotransferases were significantly lower among patients with chronic persistent hepatitis (minimal activity) than those with chronic active hepatitis (mild to moderate activity); however, overlap of values was considerable between the different histologic groups. Patients with normal serum ALT almost always show histologic evidence of chronic inflammation, although the degree of injury is typically minimal or mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/29,34,37\">",
"     29,34,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15847?source=see_link\">",
"     \"Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has also been suggested that serum ALT is an accurate marker of the response to interferon therapy. However, a meta-analysis of studies found that the serum ALT did not correlate well with the histologic change in response to therapy; there was histologic improvement in a relatively high proportion of interferon-treated patients who did not normalize their serum ALT with treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35768?source=see_link\">",
"     \"Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the general lack of correlation between liver histology and serum ALT concentrations in chronic hepatitis C, some investigators have observed that the ratio of serum AST to ALT may be useful for predicting the presence of cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In one study of 139 patients, the mean",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    ratio was higher among patients with cirrhosis than in those without cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/39\">",
"     39",
"    </a>",
"    ]. An",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    ratio &ge;1 had 100 percent specificity and 53 percent sensitivity for cirrhosis using corresponding liver biopsy specimens as the gold standard. The positive and negative predictive values were 100 and 81 percent, respectively. However, two additional series found that the predictive accuracy of this ratio was not as high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Thus, its clinical utility remains uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5446?source=see_link\">",
"     \"Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients who acquire acute hepatitis C do not spontaneously clear the virus and thus develop chronic hepatitis C. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18554?source=see_link&amp;anchor=H164590471#H164590471\">",
"     \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\", section on 'Spontaneous viral clearance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history of chronic hepatitis C has been difficult to clearly define because of the long course of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/43\">",
"     43",
"    </a>",
"    ]. Several studies have provided estimates of the proportion of patients with chronic infection who develop cirrhosis within 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/43-56\">",
"     43-56",
"    </a>",
"    ]. A systematic review of 111 studies analyzing natural history estimated that the prevalence of cirrhosis 20 years after infection was 16 percent (95% CI 14-90 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/57\">",
"     57",
"    </a>",
"    ]. Lower and higher estimates have been reported, depending in part upon the study design.",
"   </p>",
"   <p>",
"    Studies of patients who acquired acute hepatitis C from a blood transfusion generally describe no increase in all-cause mortality if the follow-up is less than 25 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In an illustrative report, all cause mortality was similar among 222 hepatitis C-related cases compared to 377 controls (67 versus 65 percent), although liver-related mortality was increased (4.1 versus 1.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/46\">",
"     46",
"    </a>",
"    ]. These observations may reflect that not all patients became chronically infected or developed significant liver disease following acute infection.",
"   </p>",
"   <p>",
"    In contrast, studies of patients who presented with chronic hepatitis tend to report a more aggressive course with a high risk of cirrhosis, decompensation, and hepatocellular carcinoma. In one series from the United States, for example, 131 patients with chronic posttransfusion hepatitis C were evaluated a mean of 22 years after transfusion: 23 percent had chronic active hepatitis, 51 percent had cirrhosis, and 5 percent had hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/47\">",
"     47",
"    </a>",
"    ]. Hepatocellular carcinoma developed in an additional seven patients an average of 36 months after the initial visit. It was estimated that the mean duration of infection among patients who developed cirrhosis was 20.6 years. Similar data were observed in studies from Japan and France [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    That the disease may not be progressive in all patients has been underscored in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/19,49,51-55\">",
"     19,49,51-55",
"    </a>",
"    ]. In a large French series, the mean time to cirrhosis was 30 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/49\">",
"     49",
"    </a>",
"    ]. It was estimated that 31 percent of patients would show no evidence of cirrhosis for at least 50 years. Similar results were described in another cohort study that followed 1980 women who had been infected with contaminated batches of anti-D immunoglobulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/58\">",
"     58",
"    </a>",
"    ]. After 25 years, overt cirrhosis or advanced fibrosis had developed in only 0.5 and 1.5 percent of the cohort, respectively, while only one patient had been diagnosed with hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/58\">",
"     58",
"    </a>",
"    ]. A separate report described 184 women who were followed without treatment and had serial liver biopsies after receiving contaminated immunoglobulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/19,59\">",
"     19,59",
"    </a>",
"    ]. During follow-up of more than 10 years, 49 percent showed no change in fibrosis, 24 percent showed regression, and only 27 percent showed progression. Baseline ALT levels correlated with histologic outcomes.",
"   </p>",
"   <p>",
"    In another report, serum samples stored between 1948 and 1954 from 8568 military recruits were analyzed for antibodies against hepatitis C and HCV RNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/53\">",
"     53",
"    </a>",
"    ]. Of 8,568 samples, 17 (0.2 percent) were positive for HCV by RIBA, of which 11 were positive for HCV RNA. During 45 years of follow-up, liver disease occurred in only 2 of the 17 patients (12 percent) who were HCV positive by RIBA. Although more patients who were HCV positive died compared with those who were HCV negative (41 versus 26 percent), only one patient (6 percent) died of liver disease 42 years after the original blood sample was obtained. On the other hand, HCV is common among US veterans and thus there are many individuals at-risk for disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality in patients with HCV is not always related to liver disease. A population-based study from Australia found that most deaths in young patients with HCV were due to continued drug use rather than from the infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reason for differences in the susceptibility to disease progression among individual patients is incompletely understood. Host and viral factors that may be significant are discussed below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Factors predictive of disease progression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies with 10 to 20 years of follow-up suggest that cirrhosis occurs in up to 50 percent of chronically infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/47,62,63\">",
"     47,62,63",
"    </a>",
"    ], although, as discussed above, lower rates of disease progression have been described. Once advanced fibrosis has developed, the risk of progressing to cirrhosis is approximately 10 percent per year. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Hepatic decompensation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Complications of hepatitis C are mostly confined to patients who have developed cirrhosis. This was illustrated in a prospective cohort study that included 838 patients with chronic HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/64\">",
"     64",
"    </a>",
"    ]. During follow-up averaging 50 months, 62 patients died (31 from liver disease and 31 from other causes). An additional 30 patients developed nonlethal complications related to cirrhosis. Thus, approximately 7 percent of the cohort developed liver-related morbidity and mortality during follow-up. The increased mortality occurred only among patients who had cirrhosis at the time of presentation.",
"   </p>",
"   <p>",
"    The development of cirrhosis is silent in the majority of patients in whom it occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/47\">",
"     47",
"    </a>",
"    ]. Although these patients tend to be more symptomatic than those with chronic hepatitis alone, no clinical symptom, physical sign, or laboratory test is either sensitive or very specific for the diagnosis. The physical examination may reveal hepatomegaly (68 percent in one series) or splenomegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/47\">",
"     47",
"    </a>",
"    ]. In our experience, however, most patients with cirrhosis do not have hepatomegaly.",
"   </p>",
"   <p>",
"    Laboratory testing can be helpful in identifying patients with chronic hepatitis C who have cirrhosis. Suggestive findings include an elevation in the serum bilirubin concentration (40 percent), hypoalbuminemia (10 percent), or a decrease in the platelet count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serum alpha fetoprotein (AFP) concentration may be mildly elevated in chronic HCV infection and does not necessarily imply the presence of hepatocellular carcinoma or cirrhosis; up to 43 percent of patients with cirrhosis without hepatocellular carcinoma have a serum AFP between 10 and 100",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/21,67\">",
"     21,67",
"    </a>",
"    ]. Nevertheless, an elevated serum AFP concentration requires imaging of the liver to rule out hepatocellular carcinoma. Serial testing for several months is warranted if the imaging studies are negative, since rising levels may be indicative of an occult malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hepatic decompensation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cirrhosis is a prerequisite for most of the major complications of liver failure in patients with chronic HCV infection; however, not all patients with cirrhosis develop these complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. A study of 384 patients with compensated cirrhosis due to HCV found that the risk of developing hepatic decompensation was 3.9 percent per year (",
"    <a class=\"graphic graphic_figure graphicRef79193 \" href=\"mobipreview.htm?25/37/26205\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/67\">",
"     67",
"    </a>",
"    ]. The most common form of decompensation was ascites, followed by variceal bleeding, encephalopathy, and jaundice (which is almost always a sign of advanced liver disease in patients with chronic hepatitis C).",
"   </p>",
"   <p>",
"    In another report of 200 consecutive patients with compensated cirrhosis at baseline, the probability of survival after diagnosis of decompensated HCV-related cirrhosis was 51 percent at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/69\">",
"     69",
"    </a>",
"    ]. Overall mortality was 43 percent after a mean of 34 months. Ascites was the most frequent initial indicator of decompensation (48 percent).",
"   </p>",
"   <p>",
"    The natural history of advanced fibrosis or cirrhosis was also examined in a large prospective trial (the Hepatitis C Antiviral Long-term Treatment against Cirrhosis Trial; HALT-C) that included 1050 patients with either advanced fibrosis (60 percent) or cirrhosis (40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/70\">",
"     70",
"    </a>",
"    ]. Among the patients with advanced fibrosis followed for four years for progression to cirrhosis, the incidence of cirrhosis was 9.9 percent per year. Over eight years of follow-up, there were 679 clinical outcomes (Child-Turcotte-Pugh [CTP] score &ge;7, variceal hemorrhage, ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, definite or presumed hepatocellular carcinoma, liver transplantation, or death). The most common clinical outcomes were CTP score &ge;7 and hepatocellular carcinoma. Clinical outcomes were more common among patients with cirrhosis compared with those with advanced fibrosis (7.5 versus 3.3 percent per year). Death or liver transplantation occurred in 12.2 percent of patients with advanced fibrosis and in 31.5 percent of patients with cirrhosis during follow-up. Once a patient developed a CTP score &ge;7, the rate of subsequent clinical events increased to 12.9 percent per year with a mortality rate of 10 percent per year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deaths associated with chronic hepatitis C in the United States are more likely to be due to end stage liver disease rather than hepatocellular carcinoma. However, HCV accounts for approximately one-third of hepatocellular carcinoma cases in the United States. Estimates of the risk of developing hepatocellular carcinoma once cirrhosis has developed have varied from 0 to 3 percent per year in various reports (",
"    <a class=\"graphic graphic_figure graphicRef53256 \" href=\"mobipreview.htm?26/21/26973\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79704 \" href=\"mobipreview.htm?36/45/37590\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. The risk appears to be greater with genotype 1b compared with genotypes",
"    <span class=\"nowrap\">",
"     2a/c",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to hepatitis B virus infection, hepatocellular carcinoma in patients with hepatitis C occurs almost exclusively in those with cirrhosis, suggesting that it is cirrhosis that is the major risk factor. However, one study found that obesity may be an independent risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/72\">",
"     72",
"    </a>",
"    ]. There is also suggestive experimental evidence that HCV infection itself can promote the development of hepatocellular carcinoma. Mice that were made transgenic for the HCV core gene developed adenomas and subsequent carcinoma within the adenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival is decreased in patients with HCV, especially in those who have developed cirrhosis. In 2007, the age-adjusted mortality rate among patients with HCV in the United States was 4.6 per 100,000 persons per year, a rate that was higher than that seen for HIV (4.2 deaths per 100,000 persons per year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/74\">",
"     74",
"    </a>",
"    ]. In addition, 73 percent of the deaths were in patients between the ages of 45 and 65 years.",
"   </p>",
"   <p>",
"    In the prospective HALT-C trial that included 1050 patients with advanced fibrosis or cirrhosis who were followed for a median of 5.7 years, 122 patients (12 percent) died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/75\">",
"     75",
"    </a>",
"    ]. The majority of deaths (62 percent) were attributed to liver-related causes. An additional 74 patients (7 percent) underwent liver transplantation. The mortality rate was higher among patients with cirrhosis compared with those who had advanced fibrosis (14 versus 7 percent).",
"   </p>",
"   <p>",
"    In the series of 384 patients with compensated cirrhosis described above, the 3, 5, and 10-year survival rates were 96, 91, and 79 percent, respectively (",
"    <a class=\"graphic graphic_figure graphicRef51057 \" href=\"mobipreview.htm?43/43/44733\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/67\">",
"     67",
"    </a>",
"    ]. Once decompensated cirrhosis occurred, the five-year survival fell to 50 percent. Similar results were found in another series in which the cumulative probability of survival free of liver transplantation was 92 percent at three years and 83 percent at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/68\">",
"     68",
"    </a>",
"    ]. Once decompensation developed, the probability of survival at three and five years declined substantially (57 and 51 percent, respectively). Survival may also be worse in patients who develop cryoglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Causes of death among patients with HCV vary based upon the age group being examined. In a population study from Denmark, the primary cause of death among patients with HCV aged 20 to 39 years was unnatural (reported as death due to mental and behavioral disorders related to psychoactive substance use and death resulting from external causes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/77\">",
"     77",
"    </a>",
"    ]. The 10-year risk of unnatural death in patients with HCV between the ages of 20 and 29 years was 13 percent. In patients between the ages of 40 and 59 years, deaths were equally distributed between liver-related, non-liver-related, and unnatural causes. In patients 70 years of age or older with HCV, the most common causes of death were non-liver related. Patients with HCV were at increased risk of death compared with non-HCV infected individuals at all ages, ranging from an 18-fold increase for 20 to 29 year-olds, to a 1.6-fold increase for patients aged 70 years or greater.",
"   </p>",
"   <p>",
"    The Centers for Disease Control estimate that 8,000 to 13,000 deaths occur each year in the United States from chronic HCV infection. Once complications of cirrhosis have occurred, liver transplantation is the only effective therapy. Recurrent HCV infection of the graft occurs in almost all patients, although the long-term survival after transplantation for HCV is similar to that for other causes of hepatic failure (60 to 80 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/5/16474?source=see_link\">",
"     \"Liver transplantation for hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FACTORS PREDICTIVE OF DISEASE PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors may be important determinants of disease progression in individual patients, including age, ethnic background, gender, HCV-specific cellular immune response, viral diversity, alcohol use, daily use of marijuana, viral coinfection, environmental factors and geography. However, even in a relatively homogeneous population such as in the Irish study discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/19\">",
"     19",
"    </a>",
"    ], the outcome is not uniform suggesting that unexplained factors influence the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Host factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observations suggest that host factors are important in the progression of chronic hepatitis C:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive fibrosis of a number of organs has been associated with production of profibrogenic cytokines. The effect of one of these cytokines, transforming growth factor B1 (TGF B1), is enhanced by angiotensin II. A study involving 128 patients with various stages of HCV related liver disease found a significant relationship between the specific TGF B1 and angiotensin phenotype and the fibrosis stage, suggesting that genetic polymorphism of these genes may be an important determinant of the fibrosis progression rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acquisition of HCV infection after the age of 40 to 55 may be associated with a more rapid progression of liver injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/49,79\">",
"       49,79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Male sex has been associated with faster fibrosis progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children appear to have a relatively decreased risk of disease progression. In one series, for example, only 1 of 37 patients with HCV RNA in serum had elevated levels of serum aminotransferases, while only 3 of 17 (18 percent) who had liver biopsies approximately 20 years after exposure had histologic signs of progressive liver disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Complications of liver disease, particularly hepatocellular carcinoma, are more common in Japan than in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/81\">",
"       81",
"      </a>",
"      ]; it is not entirely clear whether this is due only to host characteristics, or whether viral differences or the environment might also play a role. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link\">",
"       \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The host cellular immune response to HCV-specific targets appears to influence the severity of liver injury; however, its role in progressive liver injury is not clear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/82\">",
"       82",
"      </a>",
"      ]. Different genes in various HLA subregions also modulate the inflammatory response by complex interaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The progression of chronic hepatitis C is accelerated in HIV-infected patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=see_link\">",
"       \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who acquire the disease from a blood transfusion may be at increased risk for disease progression compared with those infected via other modes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/67,84\">",
"       67,84",
"      </a>",
"      ]. However, this relationship has not been confirmed in all studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who have a high body mass index and hepatic steatosis are at increased risk for the development of fibrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/80,85-89\">",
"       80,85-89",
"      </a>",
"      ]. However, the relationship between body mass, insulin resistance, steatosis, and clinical outcomes is complex. In a study of 985 patients who had been enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial (a study of long-term peginterferon), the presence of insulin resistance was the strongest predictor of clinical disease progression overall, but the risk varied according to baseline histologic features [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/88\">",
"       88",
"      </a>",
"      ]. The presence of steatosis on a baseline biopsy was associated with worse clinical outcomes in those with bridging fibrosis while lower rates of adverse clinical outcomes were observed among those with steatosis and cirrhosis at baseline. The presence of Mallory bodies and significant weight gain (&ge;5 percent) within a year of randomization were also associated with worse clinical outcomes.",
"      <br/>",
"      <br/>",
"      In other reports, the risk of fibrosis in those with steatosis was increased significantly with even moderate alcohol intake [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/90\">",
"       90",
"      </a>",
"      ]. Moderate to severe steatosis has been associated with advanced fibrosis and a decrease in response to interferon-based therapy in some reports and may be associated with insulin-resistance in the absence of obesity or diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Progression may be slower and histology less severe in African Americans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/92-94\">",
"       92-94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Daily use of marijuana has been associated with development of steatosis and more rapid fibrosis progression, possibly through stimulation of endogenous, hepatic cannabinoid receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/95-97\">",
"       95-97",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/59/13242?source=see_link\">",
"       \"Emerging therapies for hepatic fibrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Regular coffee consumption was associated with a lower rate of disease progression among participants in the HALT-C trial, a long-term study of maintenance peginterferon in patients with advanced HCV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/98\">",
"       98",
"      </a>",
"      ]. In other studies, coffee consumption has been associated with reduced hepatic fibrosis and a lower risk of hepatocellular carcinoma among patients with HCV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/99\">",
"       99",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link&amp;anchor=H170509192#H170509192\">",
"       \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Dietary factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interleukin-28B (IL28B) genotype is a known predictor of how a patient will respond to treatment with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , but its effect on the progression of fibrosis is unclear (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link&amp;anchor=H16092947#H16092947\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'IL28B polymorphisms'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study with 247 patients with chronic hepatitis C and a known date of infection found that IL28B genotype was not a predictor of fibrosis progression, though increasing age at time of infection, hepatic steatosis, male gender, and HCV genotype 3 were predictors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study with 2335 Caucasian patients with chronic HCV found that IL28B genotype was associated with the degree and the progression of fibrosis in patients with an HCV genotype other than 1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/100\">",
"       100",
"      </a>",
"      ]. Patients who had a G allele at the rs8099917 locus (ie, patients who were",
"      <span class=\"nowrap\">",
"       G/T",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       G/G)",
"      </span>",
"      were less likely than patients with the",
"      <span class=\"nowrap\">",
"       T/T",
"      </span>",
"      genotype to have significant fibrosis (Metavir stage 2 to 4) or to have rapid progression of their fibrosis (odds ratios 0.43 and 0.56, respectively). IL28B genotype was not predictive of significant fibrosis or fibrosis progression in patients with genotype 1. Interestingly, the G allele is associated with a lower likelihood of responding to treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Alcohol intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol promotes the progression of chronic HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/49,101\">",
"     49,101",
"    </a>",
"    ], even in patients with relatively low alcohol intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/102\">",
"     102",
"    </a>",
"    ]. Alcohol increases HCV replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/102,103\">",
"     102,103",
"    </a>",
"    ], and has also been linked to the acceleration of liver injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/104-106\">",
"     104-106",
"    </a>",
"    ]. In one study, for example, patients with chronic HCV infection and cirrhosis had a greater total lifetime alcohol consumption (290 versus 190 kg) and greater total alcohol consumption during the period of infection with HCV (241 versus 147 kg) than those with chronic hepatitis alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/101\">",
"     101",
"    </a>",
"    ]. As noted above, even moderate amounts of alcohol appear to increase the risk of fibrosis in patients with steatosis.",
"   </p>",
"   <p>",
"    These observations probably explain the epidemiologic reports of a high prevalence of anti-HCV in alcoholic patients with cirrhosis and liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. Thus, alcohol intake should be avoided in all patients with chronic HCV infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9496?source=see_link\">",
"     \"Hepatitis C and alcohol\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Viral factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of viral factors on disease progression is less certain. The size of the infectious inoculum (viral dose) does not appear to be important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/109\">",
"     109",
"    </a>",
"    ]. Data regarding the role of viral genotype and quasispecies in predicting outcome are too contradictory to reach definitive conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/49,110-114\">",
"     49,110-114",
"    </a>",
"    ]. As an example, while some reports have suggested that genotype 1b is overrepresented among patients with cirrhosis and those with hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/115,116\">",
"     115,116",
"    </a>",
"    ], other studies found no such association after adjusting for disease duration or patient age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/38,117,118\">",
"     38,117,118",
"    </a>",
"    ]. This suggests a cohort effect (ie, patients infected with genotype 1b having had disease for longer amounts of time).",
"   </p>",
"   <p>",
"    Another observation is that the disease may be accelerated in patients who are infected by more than one HCV genotype, suggesting that coinfection may have an additive or synergistic harmful effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/38,118\">",
"     38,118",
"    </a>",
"    ]. Similarly, coinfection with hepatitis B and C may also result in more rapid disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/119,120\">",
"     119,120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The significance of HBV and HCV coinfection may be underestimated since many coinfected patients lack serologic markers of HBV infection. This was illustrated in a study in which HBV DNA and serologic markers in 200 HBsAg negative patients with HCV were compared with controls with liver disease who were HCV negative and negative for HBV serologic markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/120\">",
"     120",
"    </a>",
"    ]. HBV DNA was present in one-third of patients with HCV despite the absence of HBsAg, and patients with HCV were significantly more likely to be positive for HBV DNA than controls (33 versus 14 percent). Furthermore, occult HBV infection was more common in patients with cirrhosis (33 versus 19 percent), and appeared to be associated with decreased interferon efficacy.",
"   </p>",
"   <p>",
"    The reason why some patients with HCV who are infected with HBV lack HBsAg is unknown. While some of these patients have hepatitis B core antibodies, in others, all markers are absent. The lack of HBsAg does not appear to be related to mutations within the gene encoding for the region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/120\">",
"     120",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30122?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\", section on 'Coinfection with HCV or HDV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, while acute infection with HBV in patients who are already infected with HCV can be associated with severe acute hepatitis, many such patients also develop a persistent decline in HCV RNA replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/121\">",
"     121",
"    </a>",
"    ]. However, as mentioned above, the chronic liver disease associated with dual infection may progress faster than chronic hepatitis due to HCV alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best clinical predictor of disease progression in chronic HCV infection is the amount of inflammation and fibrosis on liver biopsy. This relationship was illustrated in a study of 70 patients with chronic HCV infection (",
"    <a class=\"graphic graphic_figure graphicRef72654 \" href=\"mobipreview.htm?12/34/12846\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mild inflammation (portal inflammation alone or with only focal periportal extension) and no fibrosis had only a 1.2 percent annual risk of progressing to cirrhosis (",
"      <a class=\"graphic graphic_picture graphicRef53561 \" href=\"mobipreview.htm?33/0/33799\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with moderate chronic hepatitis (periportal inflammation usually involving more than 30 percent of the limiting plate) had a 4.6 percent annual risk of developing cirrhosis; more than 90 percent developed cirrhosis within 20 years of the time of the biopsy (which was not the onset of infection).",
"     </li>",
"     <li>",
"      Nearly all patients with severe inflammation or bridging fibrosis developed cirrhosis within 10 years (",
"      <a class=\"graphic graphic_picture graphicRef73535 \" href=\"mobipreview.htm?21/25/21910\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, improvement in inflammation on follow-up biopsy is also associated with less fibrosis progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stainable iron in hepatocytes has also been shown to predict progression and clinical and histologic outcomes in patients with advanced chronic hepatitis C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Predictive models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the reports discussed above have included multivariate models that can help predict disease progression in individual patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Baseline data collected as part of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial were used to develop predictive models for both clinical and histologic outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/124\">",
"       124",
"      </a>",
"      ]. The 1050 patients in the HALT-C trial were previous nonresponders to standard interferon therapies who had advanced fibrosis on liver biopsy. Clinical outcomes were defined as an increase in Child-Pugh score to seven or greater, variceal bleeding, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, and liver-related death. The histologic outcome for the study was an increase in Ishak fibrosis score of two or more points (biopsies taken at 1.5",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      3.5 years after randomization).",
"      <br/>",
"      <br/>",
"      Factors predictive of clinical outcomes on multivariable analysis were elevated",
"      <span class=\"nowrap\">",
"       AST/ALT",
"      </span>",
"      ratio, elevated total bilirubin, low albumin, low platelet count, and increasing Ishak fibrosis score. Factors predictive of histologic progression were increasing body mass index, low platelet count, and hepatic steatosis.",
"     </li>",
"     <li>",
"      In another study, clinical and laboratory variables among 247 patients with varying degrees of HCV histologic severity were analyzed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/38\">",
"       38",
"      </a>",
"      ]. Death from liver failure, the development of hepatocellular carcinoma, and liver transplantation were considered together in the statistical analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/38\">",
"       38",
"      </a>",
"      ]. A history of hepatic decompensation (defined as at least one episode of ascites, jaundice, hepatic encephalopathy, or gastrointestinal bleeding of variceal origin) and the serum albumin concentration were independent predictors of the above outcomes. Patients without a history of decompensation and a serum albumin concentration greater than 4.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (41",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      had only a 3 percent chance of developing one of the endpoints within five years versus approximately 6 percent in patients with one of these factors, and 40 percent in patients with both factors.",
"     </li>",
"     <li>",
"      In a third study of 455 patients who were followed for a median of 4.7 years, the only independent predictors of progression on multivariable analysis were sporadic transmission, advanced fibrosis, and a low albumin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/125\">",
"       125",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DISEASE COURSE DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatively few studies have examined the course of HCV infection during pregnancy. The available data are summarized separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/15/22777?source=see_link&amp;anchor=H146902198#H146902198\">",
"     \"Pregnancy in women with pre-existing chronic liver disease\", section on 'Chronic hepatitis C'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26936?source=see_link\">",
"     \"Vertical transmission of hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DISEASE COURSE DURING GLUCOCORTICOID USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic HCV can have coexisting conditions that require treatment with glucocorticoids. The effect of glucocorticoids on HCV has been best studied in the transplant setting where steroids increase HCV viral load, the clinical consequences of which are unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/5/16474?source=see_link\">",
"     \"Liver transplantation for hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with HCV exposed to glucocorticoids in the nontransplant setting also experience an increase in HCV viral load. The effect on aminotransferases is variable, although they tend to decrease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]. In an illustrative study, ten patients with chronic HCV were given a seven week course of tapering",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/126\">",
"     126",
"    </a>",
"    ]. Serum ALT levels decreased in eight patients (from 184 to 84",
"    <span class=\"nowrap\">",
"     U/L)",
"    </span>",
"    and then rebounded in seven after discontinuation. HCV RNA levels increased during therapy (by about one log) and then decreased to pretreatment values within an average of 2.8 weeks (range 1 to 5). By contrast, serum aminotransferases and bilirubin increased in another report in which treatment was continued for 16 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/128\">",
"     128",
"    </a>",
"    ]. However, there was no significant change in liver histology.",
"   </p>",
"   <p>",
"    The effect of these changes on the natural history of HCV is uncertain. It is doubtful that a short-course of glucocorticoids would have a major impact on the progression of liver disease. In patients who require long-term steroids, it is reasonable to repeat a liver biopsy in two to three years to see if histologic progression has occurred.",
"   </p>",
"   <p>",
"    The situation may be more complicated in patients with autoantibodies in whom there exists the possibility of a coexisting autoimmune hepatitis. As a general rule, treatment should first be directed toward autoimmune hepatitis because of the danger of exacerbating autoimmune hepatitis with interferon based regimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=see_link\">",
"     \"Treatment of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EXTRAHEPATIC MANIFESTATIONS OF CHRONIC HEPATITIS C",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of extrahepatic diseases have been associated with chronic HCV infection. Most cases appear to be directly related to the viral infection:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematologic diseases such as essential mixed cryoglobulinemia and lymphoma",
"     </li>",
"     <li>",
"      Renal disease, particularly membranoproliferative glomerulonephritis",
"     </li>",
"     <li>",
"      Autoimmune disorders such as thyroiditis and the presence of autoantibodies",
"     </li>",
"     <li>",
"      Dermatologic conditions such as porphyria cutanea tarda and lichen planus",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one series of 321 patients, at least one extrahepatic manifestation was observed in 38 percent (",
"    <a class=\"graphic graphic_table graphicRef66842 \" href=\"mobipreview.htm?28/9/28828\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/50/31530/abstract/129\">",
"     129",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=see_link\">",
"     \"Extrahepatic manifestations of hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30421?source=see_link\">",
"     \"Porphyria cutanea tarda and hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=see_link\">",
"       \"Patient information: Hepatitis C (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=see_link\">",
"       \"Patient information: Hepatitis C (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection with the hepatitis C virus (HCV) can result in both acute and chronic hepatitis. The acute process is most often asymptomatic; if symptoms are present, they usually abate within a few weeks. Acute infection rarely causes hepatic failure. The majority of patients with acute HCV fail to spontaneously clear the virus and develop chronic HCV. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18554?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients with chronic infection are asymptomatic or have only mild nonspecific symptoms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several studies have provided estimates of the proportion of patients with chronic infection who develop cirrhosis within 20 years. As a general rule, estimates from retrospective studies (17 to 55 percent) have been higher than prospective studies (7 to 16 percent), possibly reflecting referral bias in the retrospective studies. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survival is decreased in patients with HCV, especially once cirrhosis develops. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deaths associated with chronic hepatitis C in the United States are more likely to be due to end stage liver disease rather than hepatocellular carcinoma (HCC). However, HCV accounts for approximately one-third of HCC cases in the United States. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hepatocellular carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several factors may be important determinants of disease progression in individual patients, including age, ethnic background, gender, HCV-specific cellular immune response, viral diversity, alcohol use, daily use of marijuana, viral coinfection, environmental factors and geography. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Factors predictive of disease progression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of extrahepatic diseases have been associated with chronic HCV infection. Most cases appear to be directly related to the viral infection. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Extrahepatic manifestations of chronic hepatitis C'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/1\">",
"      Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/2\">",
"      Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/3\">",
"      Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/4\">",
"      Gonz&aacute;lez-Peralta RP, Qian K, She JY, et al. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol 1996; 49:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/5\">",
"      Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/6\">",
"      Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/7\">",
"      Grebely J, Petoumenos K, Hellard M, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/8\">",
"      Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/9\">",
"      Montes-Cano MA, Garc&iacute;a-Lozano JR, Abad-Molina C, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/10\">",
"      Mir HM, Stepanova M, Afendy M, et al. African americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data. J Clin Gastroenterol 2012; 46:e62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/11\">",
"      Alric L, Fort M, Izopet J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/12\">",
"      Thursz M, Yallop R, Goldin R, et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999; 354:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/13\">",
"      Ishii K, Rosa D, Watanabe Y, et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 1998; 28:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/14\">",
"      Kaplan M, Gawrieh S, Cotler SJ, Jensen DM. Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. Gastroenterology 2003; 125:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/15\">",
"      Haberstroh A, Schnober EK, Zeisel MB, et al. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 2008; 135:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/16\">",
"      Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/17\">",
"      Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/18\">",
"      Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009; 200:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/19\">",
"      Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/20\">",
"      Vogt M, Lang T, Fr&ouml;sner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/21\">",
"      Merican I, Sherlock S, McIntyre N, Dusheiko GM. Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. Q J Med 1993; 86:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/22\">",
"      Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/23\">",
"      Spiegel BM, Younossi ZM, Hays RD, et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/24\">",
"      Rodger AJ, Jolley D, Thompson SC, et al. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/25\">",
"      Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/26\">",
"      Piche T, Vanbiervliet G, Cherikh F, et al. Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. Gut 2005; 54:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/27\">",
"      Wilson WM, Maughan RJ. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. Exp Physiol 1992; 77:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/28\">",
"      Cacoub P, Ratziu V, Myers RP, et al. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol 2002; 36:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/29\">",
"      Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/30\">",
"      Forton DM, Allsop JM, Main J, et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001; 358:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/31\">",
"      Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/32\">",
"      Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/33\">",
"      Kramer L, Bauer E, Funk G, et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 2002; 37:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/34\">",
"      Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/35\">",
"      Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995; 90:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/36\">",
"      McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol 1996; 91:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/37\">",
"      Marcellin P, Levy S, Benhamou JP, et al. Management of the asymptomatic HCV carrier with normal ALT levels. Viral Hepatitis Rev 1996; 2:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/38\">",
"      Bonis PA, Tong MJ, Blatt LM, et al. A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. Am J Gastroenterol 1999; 94:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/39\">",
"      Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/40\">",
"      Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/41\">",
"      Imperiale TF, O'Connor JB, Vaezi MF, Richter JE. A cost-minimization analysis of alternative treatment strategies for achalasia. Am J Gastroenterol 2000; 95:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/42\">",
"      Reedy DW, Loo AT, Levine RA. AST/ALT ratio &gt; or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998; 43:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/43\">",
"      Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/44\">",
"      Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/45\">",
"      Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992; 327:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/46\">",
"      Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/47\">",
"      Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/48\">",
"      Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/49\">",
"      Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/50\">",
"      Zarski JP, Mc Hutchison J, Bronowicki JP, et al. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol 2003; 38:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/51\">",
"      Barrett S, Goh J, Coughlan B, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001; 49:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/52\">",
"      Datz C, Cramp M, Haas T, et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut 1999; 44:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/53\">",
"      Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/54\">",
"      Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology 2000; 32:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/55\">",
"      Rodger AJ, Roberts S, Lanigan A, et al. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/56\">",
"      de L&eacute;dinghen V, Trimoulet P, Mannant PR, et al. Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). J Hepatol 2007; 46:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/57\">",
"      Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/58\">",
"      Wiese M, Gr&uuml;ngreiff K, G&uuml;thoff W, et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. J Hepatol 2005; 43:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/59\">",
"      Levine RA, Sanderson SO, Ploutz-Snyder R, et al. Assessment of fibrosis progression in untreated irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol 2006; 4:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/60\">",
"      Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 2005; 41:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/61\">",
"      Amin J, Law MG, Bartlett M, et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/62\">",
"      Takahashi M, Yamada G, Miyamoto R, et al. Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/63\">",
"      Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/64\">",
"      Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/65\">",
"      Garc&iacute;a-Su&aacute;rez J, Burgaleta C, Hernanz N, et al. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br J Haematol 2000; 110:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/66\">",
"      Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001; 113:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/67\">",
"      Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/68\">",
"      Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/69\">",
"      Planas R, Ballest&eacute; B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/70\">",
"      Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011; 54:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/71\">",
"      Bruno S, Crosignani A, Maisonneuve P, et al. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/72\">",
"      Ohki T, Tateishi R, Sato T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008; 6:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/73\">",
"      Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/74\">",
"      Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/75\">",
"      Di Bisceglie AM, Stoddard AM, Dienstag JL, et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011; 53:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/76\">",
"      Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/77\">",
"      Omland LH, Jepsen P, Krarup H, et al. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol 2011; 9:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/78\">",
"      Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/79\">",
"      Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26:21S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/80\">",
"      Marabita F, Aghemo A, De Nicola S, et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011; 54:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/81\">",
"      Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26:34S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/82\">",
"      Nelson DR, Marousis CG, Davis GL, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997; 158:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/83\">",
"      Asti M, Martinetti M, Zavaglia C, et al. Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. Hepatology 1999; 29:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/84\">",
"      Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998; 28:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/85\">",
"      Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/86\">",
"      Clouston AD, Jonsson JR, Purdie DM, et al. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001; 34:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/87\">",
"      Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/88\">",
"      Everhart JE, Lok AS, Kim HY, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009; 137:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/89\">",
"      Kallwitz ER, Layden-Almer J, Dhamija M, et al. Ethnicity and body mass index are associated with hepatitis C presentation and progression. Clin Gastroenterol Hepatol 2010; 8:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/90\">",
"      Serfaty L, Poujol-Robert A, Carbonell N, et al. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol 2002; 97:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/91\">",
"      Camm&agrave; C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006; 43:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/92\">",
"      Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002; 97:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/93\">",
"      Crosse K, Umeadi OG, Anania FA, et al. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol 2004; 2:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/94\">",
"      Sterling RK, Stravitz RT, Luketic VA, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004; 2:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/95\">",
"      H&eacute;zode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/96\">",
"      Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008; 6:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/97\">",
"      H&eacute;zode C, Zafrani ES, Roudot-Thoraval F, et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008; 134:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/98\">",
"      Freedman ND, Everhart JE, Lindsay KL, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009; 50:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/99\">",
"      Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010; 51:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/100\">",
"      Bochud PY, Bibert S, Kutalik Z, et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012; 55:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/101\">",
"      Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/102\">",
"      Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/103\">",
"      Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994; 20:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/104\">",
"      Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis 1995; 15:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/105\">",
"      Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/106\">",
"      John-Baptiste A, Krahn M, Heathcote J, et al. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol 2010; 53:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/107\">",
"      Mendenhall CL, Moritz T, Rouster S, et al. Epidemiology of hepatitis C among veterans with alcoholic liver disease. The VA Cooperative Study Group 275. Am J Gastroenterol 1993; 88:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/108\">",
"      Harris DR, Gonin R, Alter HJ, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001; 134:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/109\">",
"      Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/110\">",
"      Kobayashi M, Tanaka E, Sodeyama T, et al. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996; 23:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/111\">",
"      Romeo R, Tommasini MA, Rumi MG, et al. Genotypes in the progression of hepatitis C related cirrhosis and development of hepatocellular carcinoma (abstract). Hepatology 1996; 24:153A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/112\">",
"      Honda M, Kaneko S, Sakai A, et al. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology 1994; 20:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/113\">",
"      Farci P, Melpolder JC, Shimoda A, et al. Studies of HCV quasispecies in patients with acute resolving hepatitis compared to those who progress to chronic hepatitis (abstract). Hepatology 1996; 24:350A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/114\">",
"      Seto WK, Lai CL, Fung J, et al. Natural history of chronic hepatitis C: genotype 1 versus genotype 6. J Hepatol 2010; 53:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/115\">",
"      Nousbaum JB, Pol S, Nalpas B, et al. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995; 122:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/116\">",
"      Hatzakis A, Katsoulidou A, Kaklamani E, et al. Hepatitis C virus 1b is the dominant genotype in HCV-related carcinogenesis: a case-control study. Int J Cancer 1996; 68:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/117\">",
"      Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997; 25:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/118\">",
"      Benvegn&ugrave; L, Pontisso P, Cavalletto D, et al. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997; 25:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/119\">",
"      Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997; 26:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/120\">",
"      Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/121\">",
"      Sagnelli E, Coppola N, Messina V, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/122\">",
"      Morishima C, Shiffman ML, Dienstag JL, et al. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/123\">",
"      Lambrecht RW, Sterling RK, Naishadham D, et al. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011; 140:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/124\">",
"      Ghany MG, Lok AS, Everhart JE, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010; 138:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/125\">",
"      Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/126\">",
"      Fong TL, Valinluck B, Govindarajan S, et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/127\">",
"      Magrin S, Craxi A, Fabiano C, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology 1994; 19:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/128\">",
"      Calleja JL, Albillos A, Cacho G, et al. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. J Hepatol 1996; 24:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/50/31530/abstract/129\">",
"      Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000; 79:47.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3672 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31530=[""].join("\n");
var outline_f30_50_31530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK OF CHRONIC INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SERUM AMINOTRANSFERASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hepatic decompensation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FACTORS PREDICTIVE OF DISEASE PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Host factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Alcohol intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Viral factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Predictive models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DISEASE COURSE DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DISEASE COURSE DURING GLUCOCORTICOID USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EXTRAHEPATIC MANIFESTATIONS OF CHRONIC HEPATITIS C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3672\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3672|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/61/11229\" title=\"figure 1\">",
"      Natural history hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/37/26205\" title=\"figure 2\">",
"      Cirrhosis in hep C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/21/26973\" title=\"figure 3\">",
"      Hepatocellular Ca hep C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/43/44733\" title=\"figure 4\">",
"      Survival in hep C cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/34/12846\" title=\"figure 5\">",
"      Progression hep C by liver bx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3672|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/45/37590\" title=\"picture 1\">",
"      Hepatoma Light I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/0/33799\" title=\"picture 2\">",
"      HCV hepatitis Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/25/21910\" title=\"picture 3\">",
"      HCV cirrhosis Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3672|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/9/28828\" title=\"table 1\">",
"      Extrahepatic manifestations HCV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15847?source=related_link\">",
"      Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29780?source=related_link\">",
"      Characteristics of the hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18554?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/59/13242?source=related_link\">",
"      Emerging therapies for hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9496?source=related_link\">",
"      Hepatitis C and alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/5/16474?source=related_link\">",
"      Liver transplantation for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35768?source=related_link\">",
"      Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5446?source=related_link\">",
"      Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30421?source=related_link\">",
"      Porphyria cutanea tarda and hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/15/22777?source=related_link\">",
"      Pregnancy in women with pre-existing chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26936?source=related_link\">",
"      Vertical transmission of hepatitis C virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_50_31531="Soy alternatives";
var content_f30_50_31531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nutrients to be replaced on a soy avoidance diet and alternative dietary sources",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nutrients in soy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alternative dietary sources",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein",
"       </td>",
"       <td>",
"        Meat, fish, poultry, egg, milk, peanut, other legumes, tree nuts, seeds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiamine",
"       </td>",
"       <td>",
"        Liver, pork, other meats, sunflower seeds, enriched and whole grain products, nuts and other legumes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Riboflavin",
"       </td>",
"       <td>",
"        Milk, dark green leafy vegetables, enriched and whole grains",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyridoxine (vitamin B6)",
"       </td>",
"       <td>",
"        Whole grains, seeds, meat, vegetables",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Folic Acid",
"       </td>",
"       <td>",
"        Enriched and whole grain products, beef liver, green leafy vegetables, other legumes, seeds, orange juice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium",
"       </td>",
"       <td>",
"        Milk and milk products, calcium fortified juice and calcium enriched alternative \"milk\" beverages (rice, oat, potato, hemp, almond)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphorus",
"       </td>",
"       <td>",
"        Milk, meat, fish, poultry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnesium",
"       </td>",
"       <td>",
"        Nuts, fruits, vegetables, whole grains",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron",
"       </td>",
"       <td>",
"        <p>",
"         Heme iron: Meat, fish, shellfish, poultry",
"        </p>",
"        <p>",
"         Non-heme irons: Iron fortified enriched and whole grain products, other legumes, and dried fruits",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31531=[""].join("\n");
var outline_f30_50_31531=null;
var title_f30_50_31532="Factors associated with Raynauds";
var content_f30_50_31532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders and factors associated with Raynaud's phenomenon",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rheumatological diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scleroderma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polymyositis/dermatomyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sj&ouml;gren's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Undifferentiated connective tissue disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed connective disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hematologic/oncologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraneoplastic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryoglobulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryofibrinogenemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cold agglutinin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraproteinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        POEMS syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Endocrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracic outlet syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emboli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prinzmetal angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atherosclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thromboangiitis obliterans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurological",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carpal tunnel syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migraine headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Environmental",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vibration injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frost bite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emotional stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs/toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sympathomimetic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapeutic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nicotine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ergotamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyvinyl chloride",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Block JA, Sequiera W. Lancet 2001; 357:2042. Copyright &copy; 2001 The Lancet, Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31532=[""].join("\n");
var outline_f30_50_31532=null;
var title_f30_50_31533="Natural history of MN";
var content_f30_50_31533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F61059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F61059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    High incidence of remission in untreated membranous nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 219px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Course of 100 consecutive untreated patients with idiopathic membranous nephropathy. Over a 5 year period, there was a progressive increase in the incidence of partial or complete remission, while the incidence of the nephrotic syndrome fell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Schieppati, A, Mosconi, L, Perna, A, et al, N Engl J Med 1993; 329:85.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31533=[""].join("\n");
var outline_f30_50_31533=null;
var title_f30_50_31534="Revascularization PTCA v CABG";
var content_f30_50_31534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Need for repeat revascularization is less with CABG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 349px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from six randomized, controlled trials comparing angioplasty (PTCA) with bypass surgery (CABG) demonstrate that the need for repeat revascularization with PTCA, CABG, or both is greater when the initial therapy for revascularization is PTCA rather than CABG.",
"    <div class=\"footnotes\">",
"     RITA: Randomized Intervention Treatment of Angina; ERACI: Estudio Randomizado Argetino de Angioplastia versus Cirugia; GABI: German Angioplasty Bypass Surgery Investigation; EAST: Emory Angioplasty versus Surgery Trial; CABRI: Coronary Angioplasty Bypass Revascularization Investigation; BARI: Bypass Angioplasty Revascularization Investigation.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Solomon AJ, Gersh BJ. Ann Intern Med 1998; 128:216.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31534=[""].join("\n");
var outline_f30_50_31534=null;
var title_f30_50_31535="Los Angeles grade D esophagitis";
var content_f30_50_31535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Los Angeles grade D esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Los Angeles grade D esophagitis: One or more mucosal breaks bridging the tops of mucosal folds involving more than 75 percent of the circumference of the lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_50_31535=[""].join("\n");
var outline_f30_50_31535=null;
